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ABSTRACT 
The field of biomedical optics has grown quickly over the last two decades as various 
technological advances have helped increase the acquisition speeds and the sensitivity limits 
of the technology.  During this time, optical coherence tomography (OCT) has been explored 
for a wide number of clinical applications ranging from cardiology to oncology to primary 
care.  In this thesis, I describe the design and construction of an intraoperative clinical OCT 
system that can be used to image and classify breast cancer tumor margins as normal, close, 
or positive.  I also demonstrate that normal lymph nodes can be distinguished from reactive or 
metastatic lymph nodes by looking at the difference in scattering intensity between the cortex 
and the capsule of the node.  Despite the advances of OCT in the detection and diagnosis of 
breast cancer, this technology is still limited by its field of view and can only provide 
structural information about the tissue.  Structural OCT would benefit from added contrast via 
sub-cellular or biochemical components via the use of contrast agents and functional OCT 
modalities. 
As with most other optical imaging techniques, there is a trade off between the 
imaging field of view and the high-resolution microscopic imaging.  In this thesis, I 
demonstrate for the first time that MM-OCT can be used as a complimentary technique to 
wide field imaging modalities, such as magnetic resonance imaging (MRI) or fluorescence 
imaging, using targeted multi-modal protein microspheres.  By using a single contrast agent to 
bridge the wide field and microscopic imaging modalities, a wide field imaging technique can 
be used to initially localize the contrast agent at the site of interest to guide the location of the 
MM-OCT imaging to provide a microscopic view.  In addition to multi-modal contrast, the 
microspheres were functionalized with RGD peptides that can target various cancer cell lines.  
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The cancer cells readily endocytosed bound protein microspheres, revealing the possibility 
that these protein microspheres could also be used as therapeutic agents.  These investigations 
furthered the utility of the OCT technology for cancer imaging and diagnosis.  
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CHAPTER 1 
OPTICAL COHERENCE TOMOGRAPHY 
1.1 Introduction 
Optical coherence tomography (OCT) is a high-resolution microscopic optical 
imaging technique that yields real-time multi-dimensional images of subsurface tissue 
structure [1-7]. OCT is the optical analogue to ultrasound imaging but uses light waves 
instead of sound waves to create images. Near-infrared light enables micron-scale resolution, 
providing images on the same resolution scale as histopathology. OCT is based on a 
Michelson interferometer and, when combined with a sample scanning mechanism, forms 
cross-sectional images. Since its introduction in 1991 as a method for the non-invasive 
imaging of the retina [7], OCT has capitalized on technological advances, resulting in 
significant increases in data acquisition speeds [8], added functional modalities [9-11], and 
new contrast agents [12, 13]. OCT has been evaluated in a large number of clinical 
applications including ophthalmology, cardiovascular disease, and oncology [14], to name a 
few. 
1.2 Optical Coherence Tomography in Cancer 
In recent years, the development of OCT technology for applications in the field of 
oncology has progressed rapidly. As newer scanning probes such as endoscopes, handheld 
probes, catheter probes, and needle based probes have been developed, the reach of OCT 
imaging continues to expand. For example, the development of specialized endoscopic probes 
enabled researchers to use OCT to assess lesions in the ear, nose, and throat [15-17]. OCT has 
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been successfully developed for imaging and assessing lesions in the laryngeal mucosa, oral 
cavity, oropharynx, vocal folds, and nasal mucosa [18-21]. OCT can also be used to detect 
malignancies in the gastrointestinal tract [22-25], and had a 78% accuracy rate for detecting 
dysplasia in patients with Barrett’s esophagus [26]. In the cervix, neoplastic changes in 
chromatin and nuclear morphologies contributed to significantly elevated OCT scattering 
observed in abnormal cervical epithelium compared to normal epithelium [27-29]. The 
potential applications of OCT in breast cancer are discussed in greater detail later in this 
chapter and in Chapters 2 and 3. 
1.2.1 Breast Cancer 
Breast cancer is the second leading cause of cancer deaths in women and continues to 
be the most widely diagnosed type of cancer each year in women. Earlier detection, diagnosis, 
and treatment of breast cancer continue to be the most important factors in determining the 
patient’s prognosis. Breast cancer afflicts a strikingly large number of women: 207,090 new 
cases of invasive breast cancer and 54,010 cases of in situ breast cancer were estimated for 
2010, making it the most widely diagnosed cancer in women second only to skin cancer [30]. 
The number of deaths attributed to breast cancer (39,840 expected in 2010 – second only to 
lung cancer) has started to decrease over the last few years, largely attributed to the 
effectiveness of breast cancer screening [30]. Increased awareness about breast cancer and an 
increase in breast cancer screening has led to improved detection of breast cancer lesions at 
earlier stages, resulting in smaller breast lesions and a decreased likelihood of lymph node 
involvement and cancer metastasis. The management and treatment of breast cancer has 
continued to improve as evidenced by gradual increases in the five year survival rates for all 
stages of breast cancer [31]. Currently, patients who elect for lumpectomies or mastectomies 
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typically have a sentinel lymph node dissection (SLND), which may be accompanied by the 
resection of additional axillary lymph nodes via axillary lymph node dissection (ALND) to 
help stage disease progression [31]. The staging of breast cancer is currently based on three 
main criteria: the size of the primary tumor, the infiltration of lymph nodes by cancer cells, 
and the subsequent metastasis of cancer cells to other sites. Cancer metastasis is the spread of 
cancer cells from the primary tumor site to another organ site via the cardiovascular or 
lymphatic system. The medical community has used the status of lymph nodes as one of the 
major criteria in determining the metastatic state of the cancer. In breast cancer applications, 
OCT could prove to be an invaluable tool in guiding the surgical removal of tumors, the 
assessment of lymph nodes prior to resection, and potentially the real time staging of the 
cancer. 
1.2.2 Optical Coherence Tomography in Breast Cancer 
OCT was first evaluated for imaging breast cancer tumor margins in an NMU-
carcinogen-induced rat mammary model [4]. In human breast tissue, the penetration depth of 
OCT is approximately 1-2 mm. The density of cells and sub-cellular scatterers such as the 
nuclei determine the penetration depth of OCT. High scattering signals observed in OCT 
images are often attributed to a combination of the increase in nuclear-to-cytoplasm (N/C) 
ratio and the increase in cellular density often found during the focal proliferation of cancer 
cells [29, 32]. Tissue comprised primarily of adipocytes can be imaged up to depths of 2 mm 
compared to cell-dense tumor tissue, which can be imaged up to depths of 1 mm. The 
penetration depths of OCT in these tissue types are comparable to the currently accepted 
margin widths of 1-2 mm that classify tumor margins as positive, close, and negative. 
Compared to the current standard of care, which calls for the pathological evaluation of 
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stained fixed or frozen sections, OCT can provide an assessment of the tumor margin in 
minutes. This real time feedback would allow surgeons to immediately resect additional 
tissues if necessary.  
In the assessment of lymph nodes, OCT was first evaluated in a rat animal model and 
ex vivo human lymph nodes using an laboratory based OCT system centered at 800 nm [33]. 
These initial laboratory based studies demonstrated that OCT could penetrate through the 
lymph node capsule, and assess sub-capsular morphological changes in the cortex of the node. 
These differences in scattering intensities can be used to distinguish normal nodes from 
reactive and metastatic nodes. By being able to image through the capsule, OCT can assess 
the nodal status without compromising the structural integrity of the lymph node. Currently 
the primary purpose for resecting lymph nodes during breast cancer surgeries is for disease 
staging. A significant portion of the resected lymph nodes (> 50-75%) is classified as normal 
based on histopathological analysis. The risk for developing lymphedema could be vastly 
decreased by reducing the number of non-diagnostic or normal lymph nodes surgically 
removed during sentinel lymph node and axillary lymph node dissection procedures. 
Needle-based OCT probes have previously been used to provide access to deeper 
breast lesions a few millimeters beneath the tissue surface [34-36]. These needle probes are 
fiber based and can provide real-time information for guided lesion biopsy or for placement of 
localization wires [34, 36]. Currently there are significant difficulties in guiding needle 
biopsies using ultrasound and x-ray imaging techniques due to sub-optimal contrast and only 
two-dimensional images provided to guide the needle. Coupling an OCT probe to the tip of 
the biopsy needle could provide real-time diagnostic information that could facilitate guiding 
the biopsy needle. Reports identified diagnostically significant information within the optical 
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backscattering and refractive index signals of the breast tissue, which can distinguish various 
breast tissue types [4, 37, 38]. These same diagnostic properties can be extracted from 
individual axial scans that comprise an OCT image, or from spatial information provided by 
the OCT image itself [36-38]. 
These studies represent the first demonstrations of OCT in the field of breast cancer. 
By enabling surgeons to rapidly visualize tissue morphology beneath the surface and over 
large surface areas while preserving tissue structure, OCT has the potential to become an 
invaluable tool for the surgical guidance of breast cancer surgeries. The intraoperative use of 
OCT in the assessment of tumor margins and lymph nodes during breast conserving surgeries 
will be further discussed in Chapters 2 and 3. 
1.3 Optical Coherence Tomography in Cardiovascular Applications 
Over the past decade, OCT has been extensively explored for various cardiovascular 
applications. OCT, spectroscopic OCT, and polarization sensitive OCT have been used to 
examine the structural integrity of the coronary artery [39-51]. The development of catheter-
based probes, increased acquisition speeds, and the introduction of functional extensions of 
OCT have greatly increased the potential value of this technology for cardiovascular 
applications. Newer probes can integrate the OCT sample-arm optics into existing 
intravascular catheters for both forward and radial OCT imaging [47, 52]. 
Intravascular OCT has been successfully used in the characterization and visualization 
of cardiac interventions, such as percutaneous coronary intervention (PCI) and stent 
implantations [39, 41, 44, 46, 49, 50, 53, 54]. In cases of chronic total occlusion of a coronary 
artery, OCT can be used to guide the guide wire and decreases the chances of perforating the 
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artery and causing dissection of the intima [55, 56]. In the application of stent placement, 
OCT imaging can give surgeons a real-time visualization of stent apposition [40, 57], as well 
as provide greater information about stent integrity, neointimal proliferation, and 
neovascularization [58-60]. High-resolution in vivo OCT imaging can be used in real-time to 
guide the optimal placement and deployment of stents, assess the overexpansion of stents, 
identify post-stenting vessel injuries [40, 61], and assess stent failures such as restenosis and 
stent thrombosis. 
1.3.1 Atherosclerosis 
Atherosclerosis is a condition in which materials such as cellular waste, fatty 
substances, cholesterol, calcium, and fibrin accumulate within the inner lining of an artery. 
Atherosclerosis currently accounts for over 75% of cardiovascular diseases (CVDs) including 
strokes, which make up 18% of CVDs [62]. Vulnerable plaques are often caused by an 
inflammatory response and are found in medium- to large-sized arteries. Plaques are a key 
component in the development of atherosclerosis and CVDs in general. Recent research has 
focused not only on the detection of plaques but also more importantly on their potential for 
rupture. Distinguishing characteristics of vulnerable plaques include a thin fibrous cap, a large 
lipid pool, and an increase in macrophage activity. The greatest risk posed by plaques is the 
sudden rupture of the fibrous cap and resulting blockage of vessels downstream from the site 
of the plaque, which can lead to strokes and heart attacks. 
1.3.2 Optical Coherence Tomography in Atherosclerosis 
The ability to locate and assess the status of atherosclerotic lesions is an increasingly 
important issue [62]. Cardiovascular OCT imaging can be used to visualize vulnerable 
plaques in the coronary or carotid arteries and evaluate their potential for progression or 
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rupture. This assessment would be performed after suspicious areas had been localized using 
other imaging modalities such as CT, ultrasound, or fluoroscopy. Intravascular OCT imaging 
is limited by the tissue penetration depth and blood-induced signal attenuation, which can be 
reduced with saline flushes or vascular balloon occlusion prior to OCT imaging [44]. 
OCT has been demonstrated for the in vivo quantification of activated macrophage 
content in plaques and for the differentiation of plaque type [50, 63]. Plaque identification has 
been demonstrated with high sensitivity and specificity (fibrous tissue – 87%, 97%; 
fibrocalcific– 95%, 100%; lipid-rich – 92%, 94%). The OCT-quantified macrophage density 
located underneath the fibrous cap has been directly correlated with the patient’s clinical 
presentation. The presence of activated macrophages near the endothelial layer is thought to 
contribute to the instability of a vulnerable plaque [49, 63, 64]. OCT has been used to 
characterize the attenuation and layer thickness changes associated with arterial wall 
components such as the intima, media, lipid-rich regions, and calcifications [58, 65-67]. 
1.4 Importance of the Alpha (v) Beta (3) Integrin Receptor in Angiogenesis, Cancer, and 
Atherosclerosis 
Angiogenesis is the development and growth of new blood vessels and occurs during 
the formation of tumors and in the development of atherosclerosis. New blood vessel 
formation is needed to support the growth of tumors larger than a few millimeters in size. 
Integrin receptors – heterodimer transmembrane proteins – have been widely reported as key 
players in angiogenesis and the proliferation of cancer metastases. With over 25 known 
integrin receptors, the one that has been targeted for the work presented in this thesis is the 
αvβ3 integrin receptor because it has been well characterized to be upregulated during the 
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angiogenesis process that would accompany inflammatory processes but in particular in 
cancer [68, 69] and atherosclerosis [70-72]. Integrins mediate cell-substrate adhesion and are 
often overexpressed in cancer cells, particularly in metastatic cancer cells. These circulating 
tumor cells may metastasize to other organ systems via the cardiovascular or lymphatic 
system. The αvβ3 integrin receptor has been known to be overexpressed in the development of 
tumor angiogenesis, cancer metastasis, and atherosclerosis. The arginine-glycine-aspartate or 
RGD sequence motif can be used as a label to target angiogenesis, cancer cells [73-109], and 
atherosclerotic plaques [70-72, 110-116]. During tumor angiogenesis, newly formed vessels 
surrounding the tumor are often leaky, tortuous, and highly unstructured. The blood flow is 
slower and not necessarily unidirectional in this random and disordered network of vessels. 
This environment could potentially be beneficial for trapping larger particles such as protein 
microspheres at the tumor site. 
1.5 Optical Coherence Tomography 
OCT is analogous to ultrasound employing the backscattered light waves instead of 
the backscattered sounds waves to create the OCT image. OCT or low coherence 
interferometry (LCI) can be performed using a Michelson type interferometer. A light source 
with low temporal coherence is split into two beams: a reference arm and a sample arm. The 
interference of the back reflections from the two arms is collected at the photodetector. Only 
back reflections that are within the coherence length will provide constructive interference. 
The coherence length determines the axial resolution along the depth of the OCT image. 
Using the optical coherence gating, all of the other back reflections not within the coherence 
length of the reflection coming back from the reference arm will be neglected. Using this 
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gating method, the localization of individual scatters in the sample can be resolved. The 
transverse resolution of OCT is determined by the objective used to focus the OCT beam onto 
the sample. Time-domain OCT systems physically scan the reference arm to move the optical 
coherence gate up and down along the axial direction. The development of spectral-domain 
OCT or swept-source OCT combined with faster detection systems has increased the OCT 
imaging speeds by several orders of magnitude [117-122]. 
For the intraoperative assessment of tumor margins and lymph nodes discussed in 
Chapters 2-3, I designed and built a portable spectral-domain OCT system using a super 
luminescent diode (SLD) (Model SLD1C, B&W Tek, Inc., Newark, Delaware) centered at 
1310 nm with a bandwidth of 92 nm. Light is first passed through an optical circulator 
(CIRC-3-31-P-BB-10-6:3 port, Gould Fiber Optics, Millersville, Maryland) and into a 95/5 
fiber-optic splitter (Gould Fiber Optics, Millersville, Maryland) that divides the light into a 
sample and reference arm. The sample arm focuses ~4.75 mW of light onto a 35.0 µm spot 
size (transverse resolution) using a 60 mm achromatic lens. A 60 mm focal length achromatic 
lens in the sample arm focuses 4.75 mW of light to a 35 µm spot (transverse resolution). The 
confocal parameter was 1.47 mm to closely match the OCT image depth of 2.0 mm. The 
broad bandwidth source yields an axial resolution of 8.2 µm in air or 5.9 µm in tissue. 
Reflected light from the sample and reference arms is passed through polarization controllers 
(FPC-2, Fiber Control, Holmdel, New Jersey), coupled into an interferometer, spectrally 
dispersed by a diffraction grating (53004BK01-148R, Richardson Gratings, Newport 
Corporation, Rochester, New York, 1000 grooves / mm and blazed for 1310 nm), and focused 
onto an Indium Gallium Arsenide (InGaAs) line camera (SU1024LE-1.7T1-0500, Sensors 
Unlimited, Inc., Goodrich Corporation, Princeton, New Jersey) with a 150 mm singlet lens. 
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Camera exposure times range from 24.4 µs to 408.4 µs, corresponding with measured signal-
to-noise ratios of 96 dB to 116 dB. The imaging system acquires OCT images at a rate of 
~5,000 axial scans per second or up to ~8-9 images per second (~600 axial scans / 10 mm). 
The sample is laterally scanned under the OCT beam using an automated translation stage. 
Data are collected using a high-speed data acquisition card with a 5 MHz sampling rate and 
12-bit quantizer (PCI-6111E, National Instruments Corporation, Austin, Texas) in a dual 
Xeon processor (3.20 GHz) computer with 1 GB of RAM. Acquisition and processing time 
for an OCT image was ~5 seconds / image. The OCT hardware and data acquisition are 
controlled by custom software written in LabVIEW and interfaced with a data processing 
sequence written in Matlab/C++. 
Due to the non-linear response from optical components, a cubic spline interpolation 
and resampling technique is implemented to resample the spectrum into a more uniform 
frequency space [123]. The most optimal spline interpolation parameters were calculated 
using data collected by placing a perfect reflector placed at the focus of the sample arm while 
the reference arm was moved through a range of optical path lengths corresponding to the full 
depth of the OCT image. The collected data was compiled to create a Modulation Transfer 
Function (MTF). The spline interpolation parameters were optimized to give the flattest MTF 
possible. The up-sampled data was re-indexed in the frequency domain using the spline 
interpolation. Lastly, an inverse Fourier transform was taken to bring the data from the 
spectral-domain back to the time-domain producing a traditional two-dimensional OCT 
image. 
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Figure 1.1: Schematic of the clinical spectral-domain optical coherence tomography (SD-
OCT) system. Light from a superluminescent diode (SLD) (λ=1310 nm) is directed into an 
optical circulator (OC) and to a fiber coupler (FC) that splits 5% of the light to the reference 
arm mirror (RM) and 95% of the light to the sample arm containing focusing optics and an 
automated x-y translation stage (TS). Light is collimated through fiber collimators (Col). 
Reflected light from each arm is coupled through polarization paddles (PP), interfered within 
the fiber coupler, and spectrally dispersed onto a line camera. 
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During the development of the clinical instrument, several issues were considered and 
addressed which affect the overall performance of the system ranging from the choice of the 
laser source (power vs. bandwidth), the confocal parameter and transverse resolution of the 
sample arm, the penetration depth, the performance of the spectrometer, and the SNR of the 
system. The bandwidth of the optical light source was a more dominant contributor to 
increasing the axial resolution then the power of the light source. In order to validate the 
clinical OCT system, the same human breast cancer sample was imaged under the clinical 
SD-OCT system (1310 nm CW, 90 nm BW, 116 dB SNR, 5000 lines / sec acquisition rate), 
the laboratory-based time-domain OCT (TD-OCT) system (800 nm CW, 120 nm BW, 106 dB 
SNR, 10 lines/sec acquisition rate), and the laboratory-based SD-OCT system (800 nm CW, 
120 nm BW, 96 dB SNR, 29000 lines / sec acquisition rate). The results show that although 
the resolution of the clinical SD-OCT system is lower than in the 800 nm systems (this is 
expected due to the smaller bandwidth) there was still remarkable agreement between the 
three systems in identifying the tumor margin in the sample (Figure 1.2). 
The penetration depth of OCT is determined by several factors including the 
wavelength and power of the light used, and the density distribution of scatterers in the path 
of the light. OCT is largely performed using light in the NIR region where forward directed 
scattering dominates and there is minimal absorption by major biological components such as 
hemoglobin, water, melanin, to name a few. This therapeutic window is 600-1300 nm. The 
density and types of scatterers in the sample also affect the OCT penetration depth since OCT 
detects single scattering events. As the density of scatterers or as the penetration depth 
increases, the number of multiple scattering events increase thereby decreasing the signal to 
noise ratio and OCT penetration depth.   
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(a) Laboratory Bench-Based System (800 nm,time-domain OCT) 
 
(b) Laboratory Bench-Based System (800 nm,spectral-domain OCT) 
 
(c) Clinical Portable System (1300 nm,spectral-domain OCT) 
Figure 1.2: OCT images of the same tissue sample across three different OCT systems. The 
laboratory bench-based system uses a Ti:Sapphire laser centered at 800 nm, which feeds into 
a time-domain OCT system (a) and a spectral-domain OCT system (b). The clinical portable 
system uses a 1300 nm SLD and is a spectral-domain OCT system (c). 
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1.6 Functional Extensions of OCT 
As the field of OCT has matured, there has been a greater push to develop strategies 
that would improve the molecular and cellular sensitivity of OCT [12, 13, 124-133]. There are 
two main methods for adding molecular information to the field of OCT imaging. The first is 
through the extension of the coherence gating to detect non-structural phenomenon. For 
example, pump-probe OCT uses a pump-probe source to probe the ground state absorption of 
molecules [127]. Nonlinear Interferometric Vibrational Imaging (NIVI) probes the molecular 
vibrations of the sample using an interferometer setup to detect the coherent anti-Stokes 
Raman scattering (CARS) signals [129, 133]. In CARS imaging, the specimen is probed with 
both a pump frequency and a Stokes frequency, where the difference between the two 
frequencies is the Raman resonance frequency of interest [129]. The anti-Stokes pulse can 
then be measured. NIVI is able to measure both the amplitude and phase of the CARS signal, 
which allows researchers to filtering out the nonresonant background [129]. Under 
magnetomotive OCT (MM-OCT), an external magnetic field is modulated during OCT 
imaging causing the magnetic particles to physically displace nearby scatterers [13, 132]. 
MM-OCT can detect these changes in the displacement of the scatterers. Another functional 
extension of OCT is spectroscopic OCT (S-OCT), which provides quantitative information 
about the presence of near infrared region (NIR) dyes in the specimen or other strongly 
absorbing particles in the wavelength region of the OCT light [128, 134, 135]. With 
polarization-sensitive OCT (PS-OCT), the tissue birefringence is measured by detecting the 
change in the polarization of the back-scattered light caused by the specimen [124]. Changes 
in the ordered structure such as the actin filaments in muscle tissue or of collagen in skin has 
been thought to be attributed to the birefringence signal that can be measured with PS-OCT. 
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1.6.1 Magnetomotive Optical Coherence Tomography 
MM-OCT is a novel method that was recently developed for providing additional 
contrast to OCT [10, 132, 136-139]. A solenoid placed just above the sample can induce a 
magnetic field strength ranging from 600 to 900 Gauss dependent on the driving voltage. This 
particular geometry allows the OCT imaging beam to pass through the central bore of the 
solenoid. Under this configuration, the magnetic field gradient is primarily in the axial 
direction along the same path as the OCT imaging beam and all radial components of the 
magnetic field are considered to be negligible within the OCT imaging volume. 
Magnetomotion occurs when the applied magnetic field exerts a force on the magnetic 
particle along the axial direction (Figure 1.3). The motion of the magnetic particle physically 
displaces nearby scatterers, detected as a change in the OCT interferogram (Figure 1.3). The 
amplitude of the displacement is determined by the concentration of magnetic particles and 
the viscoelastic properties of the medium. Both higher magnetization and higher 
concentrations of the magnetic particle result in larger displacements of nearby scatterers. As 
the stiffness of the medium increases, the amplitude of the displacement decreases. 
Using difference imaging, an OCT image is taken when the magnetic field is turned on 
and a second OCT image is taken when the magnetic field is turned off. The magnetomotive 
function can be added to either time-domain or spectral-domain OCT systems. In the case of 
time-domain MM-OCT, the field is turned off and on at each axial scan position along the 
transverse direction. Under spectral-domain MM-OCT, two images are acquired: one with the 
magnetic field modulated and the second OCT image with the field off. A sample schematic 
diagram of a time-domain MM-OCT system is depicted in Figure 1.4. 
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Figure 1.3: Magnetomotion in Magnetomotive Optical Coherence Tomography (MM-OCT) 
(courtesy of Amy Oldenburg). 
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Figure 1.4: Schematic of a time-domain Magnetomotive OCT (MM-OCT) system.  
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1.7 Contrast Agents in OCT 
The second method for extending the molecular sensitivity of OCT is through the 
development and use of exogenous contrast agents. Many different types of contrast agents 
have been developed for OCT and related imaging modalities that span a range of sizes and 
structures [140]. Protein microspheres have been modified for OCT imaging by incorporating 
gold nanoparticles into their protein shell to increase optical scattering [141]. Encapsulating 
iron oxide into protein microspheres provides MM-OCT contrast [142]. A more detailed 
discussion on the development of protein microspheres and protein microspheres as a contrast 
agent can be found in Chapters 4-5. Gold nanoshells, another class of OCT contrast agent, 
exhibit a large backscattering cross-section, which contributes significant OCT contrast in 
tissue phantoms at concentrations near 109 mL-1 [143, 144]. Hollowed-out gold nanocubes 
called nanocages (37 nm in size) can be detected at 1 nM concentrations using OCT [145]. 
Gold nanorods that are less than 45 nm in size provide absorption-based OCT contrast and 
can be detected at concentrations of 30 ppm [146]. Magnetic iron oxide nanoparticles were 
the first contrast agents to be developed for use with MM-OCT. These nanoparticles are 
perturbed using an externally modulated magnetic field which causes the physical 
displacement or magnetomotion of nearby scatterers providing the MM-OCT contrast 
previously described [132]. 
1.8 Summary 
OCT is an interferometric imaging technique that provides real-time, high-resolution 
cross-sectional images of samples. OCT has been used in a wide number of biomedical 
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applications and has shown to be most successful in ophthalmology, cardiovascular 
applications, and oncology. Within the field of oncology, OCT has been shown to be quite 
successful in identifying tumor lesions in a number of clinical fields primarily because of the 
increased scattering observed with tumor cells. This increased scattering is largely attributed 
to the increased chromatin and increased nuclei to cytoplasmic (N/C) ratio commonly found 
in rapidly dividing cancer cells. The use of OCT for assessing tumor margins during breast 
conserving surgeries will be further discussed in Chapter 2. The intraoperative assessment of 
lymph nodes using OCT will be described and discussed in Chapter 3. 
The endogenous OCT contrast is dependent on backscattered light provided by the 
sample, which is interfered with the light from the reference arm. The larger the change in 
refractive indices at boundary surfaces, the stronger the reflections detected by OCT. Many 
advances have increased the acquisition speed and resolution of the core OCT imaging 
technology. The most novel advances have been in the translation of OCT from a purely 
cellular imaging technique towards a molecular imaging technique. Molecular contrast can 
enhance OCT and is provided by new functional extensions such as pump-probe OCT or 
spectroscopic OCT, or with contrast agents. The use of contrast agents is potentially much 
more advantageous as it provides a method for adding exogenous contrast to samples, 
completely independent of the endogenous contrast from the specimen. 
The development of protein microspheres as a targeted multi-modal contrast agent will 
be discussed in Chapters 4-5. The in vitro targeting and cellular uptake of RGD-coated and 
non-coated microspheres will be addressed in Chapter 6. Preliminary ex vivo and in vivo 
targeting studies of protein microspheres to the αvβ3 integrin receptors will be discussed. 
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Chapter 7 will focus on the future directions and conclusions of the work presented in this 
thesis. 
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CHAPTER 2 
OPTICAL COHERENCE TOMOGRAPHY IN TUMOR MARGIN ASSESSMENT 
2.1 Introduction 
2.1.1 Tumor Margin Assessment and Local Recurrence 
As lumpectomy rates increase over time, the definition of a clean surgical margin 
continues to change. A recent study of radiation oncologists reported that 45.9% defined 
negative margins as no cancer cells at the inked margins; whereas, 7.4% defined them as no 
cells within 1 mm, and 21.8% believed them as no cells within 2 mm [1]. As more studies 
correlated the width of uninvolved margins to local recurrence [2, 3], more aggressive 
approach towards breast conservation allow surgeons to use 2 mm, or even 1 mm, to define a 
clean margin. The same survey of radiation oncologists reported that 31% of respondents 
defined a close margin as having no cells within 1 mm, and an additional 38% defined it to be 
no cells within 2 mm of the inked surface [1].  
Despite this debate, the key predictor of local recurrence is the margin status [4-15]. A 
positive margin, the presence of disease on the inked surface, occurs in at least 30-35% of 
surgical cases, and an additional 10-15% are classified as close margins (< 2 mm) [14]. Local 
recurrence rates for breast conserving therapy followed by radiation were reported in 2-28% 
of cases with positive margins, 2-16% with close margins (< 2 mm), and 2-8% with negative 
margins [14] which would be higher in the absence of radiation therapy [5, 7, 16, 17]. 
2.1.2 Intraoperative Margin Assessment 
Currently, no real-time non-destructive intraoperative method exists to rapidly assess 
the microscopic status of lumpectomy margins as a standard of care [18, 19]. Several 
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techniques have been investigated including frozen section analysis (FSA), touch prep 
cytology, radiography, radiofrequency (RF) spectroscopy, and Raman spectroscopy. FSA has 
a sensitivity of 73.08% and a specificity of 98.32% compared to paraffin section analysis 
(PSA) in breast cancer [18]. FSA is not widely accepted as part of a standard of care due to 
difficulties in performing frozen sections on adipose tissue, added time (~20-30 minutes), 
increased operating room time, and increased costs associated with further pathology 
evaluation. The most significant disadvantage with FSA is the inability to be performed over 
the entire surface area of the tissue specimen, sharing the same sampling rate limitation as 
PSA in sampling only 10-15% of the surface area [20]. 
Touch prep cytology can rapidly assess the entire surface area, addressing the 
sampling rate issue while preserving the integrity of the specimen, and making it a promising 
technique for identifying positive margins. This technique reported sensitivities of 75% and 
specificities of 82.8% [20]. The major disadvantages include the need for tumor cells at the 
surface, and their detachment. Touch prep cytology does not provide information about the 
presence of cancer cells beneath the surface and therefore is unable to determine close and 
negative margins. 
Intraoperative radiography of specimens provides surgeons with the ability to 
visualize margins in depth by displaying two-dimensional x-ray projections. However, the 
low reported sensitivity and specificity of 49% and 73%, respectively [21], are primarily due 
to the inability to identify diffuse microscopic processes, especially where the tumor boundary 
is poorly defined [22]. 
RF spectroscopy provides a bulk measurement over a circular area (0.7 cm diameter) 
and within a 100 µm depth [23]. With low sensitivity (71%) and specificity (68%) [23], 
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shallow penetration depth, and low resolution, detection within 1-2 mm for margin 
classification is limited. Raman spectroscopy, which extracts chemical information, was 
reported to have a sensitivity of 100%, a specificity of 100%, and an overall accuracy of 93% 
in identifying carcinomas [24]. Despite high sensitivity and specificity, this technique may 
have limited clinical utility because the required point measurements with long 1 second 
acquisition times per point prevent sampling of large surface areas. 
2.2 Portable Clinical Spectral Domain Optical Coherence Tomography System 
A clinical spectral-domain OCT (SD-OCT) system (Figure 2.1) was constructed to 
assess surgical margins from lumpectomy specimens. This OCT system was previously 
described in detail previously in Chapter 1 Section 5. The system employs a                     
super-luminescent diode (SLD) (Model SLD1C, B&W Tek, Inc., Newark, Delaware), with an 
optical spectrum centered at 1310 nm and a bandwidth of 92 nm. Approximately 4.75 mW of 
light is focused onto a 35 µm spot (transverse resolution) on the sample. The broad bandwidth 
source yields an axial resolution of 8.2 µm in air or 5.9 µm in tissue. The depth-of-field of the 
lens (1.47 mm) closely matches the penetration depth of OCT in human breast tissue. The 
camera exposure time ranges from 24.4 µs to 408.4 µs, corresponding to measured signal-to-
noise ratios of 96 dB to 116 dB. OCT images are acquired at a rate of ~5,000 axial scans per 
second or up to ~8-9 images per second (~600 axial scans / 10 mm). Acquisition and 
processing time for an OCT image was ~5 seconds / image. The data is assembled, processed 
as previously described, and displayed as a two-dimensional image. 
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Figure 2.1: Photograph of the clinical SD-OCT system housed in a standard endoscopy cart 
(left). This system is portable for use in various surgical suites. Resected surgical specimens 
are placed on the sample-arm stage (a). The detector and reference arm (b) are located within 
the cart, along with the light source and hardware controllers (c) and computer (d). OCT 
images (shown in later figures) represent two dimensional cross-sectional planes (x-z) 
oriented perpendicular to the tissue surface (right). Multiple OCT images can be acquired by 
stepping the beam in the y direction.  
 44 
2.3 Clinical Study 
Patients identified and recruited for this study had primary breast tumors (both in situ 
and invasive carcinoma) in need of surgical resection by breast-conserving surgery, as 
determined by physicians at Carle Foundation Hospital and Carle Clinic Association, Urbana, 
Illinois, based on pre-operative radiological films, biopsy results, or other relevant diagnostic 
information. Patients undergoing mastectomy were excluded due to decreased likelihood of 
positive or close margins. No patients were excluded due to age or race. Patients were 
informed and consented prior to surgery per protocols approved by institutional review boards 
at the University of Illinois at Urbana-Champaign and Carle Foundation Hospital. 
After surgical tissue resection but prior to margin assessment by the radiologist or 
pathologist, the initial lumpectomy specimen was imaged in the operating room using OCT 
(Figure 2.1). A series of 10-20 parallel images were taken over a 1.0 x 1.0 cm area. The 
researchers involved in image acquisition varied between imaging sessions and neither the 
surgeon nor staff disclosed any information about the specimen during the imaging sessions. 
Regions selected for OCT were based on suspicious visual or palpable findings as determined 
by the researchers, or were the entry-exit sites of localization guide wires. Following OCT 
imaging, one imaging site per specimen was marked with ink for correlation with 
histopathology, and the specimen was returned to surgical staff for standard processing and 
pathological margin assessment. In addition to histology sections acquired for diagnostic 
purposes as part of a standard of care, sections co-registered with intraoperative OCT were 
acquired, stained, and correlated. 
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2.3.1 Patient Information 
A total of 37 female patients were enrolled in the study. The training set consisted of 
17 patients with a mean age of 62 (range from 44 to 82) and the study set consisted of 20 
patients with a mean age of 66 (range from 41 to 84). Their diagnoses, based on pathological 
findings and tumor margin assessments, included 15 cases of ductal carcinoma in situ, 1 case 
of lobular carcinoma in situ, 2 cases of infiltrating ductal carcinoma, 9 cases of invasive 
ductal carcinoma, 1 case of invasive papillary carcinoma, 2 cases of invasive mammary 
carcinoma, and 1 case of atypical ductal hyperplasia. The majority had more than one 
diagnosis classification associated with their histopathological assessment. An additional two 
patients in the training set and two in the study set were consented but subsequently excluded 
from the study and OCT imaging due to changes in surgery schedules or procedures. 
2.4 OCT Image Processing & Evaluation Protocol 
All OCT images were processed with the same standardization method and displayed 
on the same intensity scale [25]. OCT images were initially evaluated in real-time by one of 
several researchers trained on the characteristic features found on OCT of breast tissue to 
ensure that the images were of sufficient quality for evaluation and to ensure that a subset of 
the images collected contained diagnostic features. Using criteria established from the training 
set, a single researcher during a single session, several months after the data sets were 
acquired, evaluated all OCT images and identified normal or abnormal features. Since the 
OCT imaging depth is approximately within the same 2 mm range that pathologist used to 
define a close margin, OCT images with abnormal features were classified as positive. The 
observed OCT image features were thought to be indicative of either invasive or in situ 
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carcinoma. OCT margin assessment was made using the entire set of available OCT images 
(10-20 images) taken at each imaging site and was correlated with the respective histological 
section from that site.  
2.5 Histology Image Evaluation Protocol 
Histology sections were acquired from marked areas imaged in the operating room 
with OCT. All tissue sections were stained with hematoxylin and eosin (H&E) and some were 
additionally immunohistochemically stained as determined by the pathologists and the 
pathology staff. Histology slides were digitized using a light microscope at 4X magnification 
and stitched together (Adobe Photoshop) to produce a single image. The compiled montage 
was oriented based on inked borders for later correlation to OCT images. A board-certified 
pathologist classified the H&E-stained histology images either as invasive carcinoma, in situ 
carcinoma, other non-normal tissue, or normal tissue. Margins identified as carcinoma or 
other non-normal tissues were considered to be positive. The pathologist was blind to the 
OCT images and results so that an independent and unbiased assessment of the histology slide 
corresponding to the matching OCT image set could be made. 
2.6 Training Data Set 
An initial training data set of 78 OCT images from 17 patients (min = 2, max = 10, 
avg = 5 images / specimen) were used to establish standard imaging protocols, co-registration 
procedures, and image evaluation criteria of the surgical margins. Representative images 
shown in Figure 2.2 include normal adipose tissue (Figure 2.2a), surgical artifacts of surface 
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blood (Figure 2.2b) and cauterized tissue (Figure 2.2c), areas that appear duct-like in shape 
(Figure 2.2d and Figure 2.2e), and areas of highly scattering cells with spatially 
heterogeneous scattering intensity (Figure 2.2f). These results were confirmed by gross visual 
findings or by histopathological analysis. Histopathological analysis reported DCIS 
involvement for the specimen imaged in Figure 2.2f. 
The training data set findings were used to establish methodologies used in subsequent 
analyses for identifying positive margins. These criteria include the presence or absence of 
high-intensity scatterers, the location of these scatterers throughout the tissue, the 
heterogeneous/homogeneous spatial distribution of scattering intensity, and the morphological 
characteristics of these regions of interest. Surgical artifacts that could interfere with OCT 
evaluation such as surface blood and cauterized tissue appeared as contiguous and highly 
scattering areas, remained localized to the immediate surface, and were quickly identified 
visually in the imaging field. In Figure 2.2b, a thin film (< 100 µm) of homogeneous 
scatterers represented a bloody surface, while in Figure 2.2c, the cauterized tissue produced a 
highly scattering area which was observed within ~300 µm of the tissue surface. The region 
of interest in Figure 2.2d had both a high scattering intensity and a more heterogeneous 
composition indicative of cancerous tissue. In Figure 2.2d, the presence of highly scattering 
regions deep in the margin, instead of localized to the immediate surface, suggested that these 
features were intrinsic to the tissue architecture rather than a result of the surgical procedure. 
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Figure 2.2: Representative OCT images of surgical margins from lumpectomy specimens 
acquired for the training set. Images of normal tissue (a) were identified by the homogenous 
pattern of large adipose cells. Readily identified surgical artifacts included blood (b), which 
appeared as a thin film of scatterers, and cauterized tissue (c), which had a patch-like 
appearance. Image of a potential duct (d) with a mixed distribution of low and high scattering 
areas. Images of positive margins (e & f) containing tumor cells and tissue represented by a 
highly scattering area that was more heterogeneous and disruptive compared to the 
surrounding tissue architecture. 
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2.7 Study Data Set 
OCT images with histological correlations from an additional 20 patients were used 
for the study set. A total of 210 OCT images were acquired from 20 lumpectomy specimens 
with an average of 10 OCT images per specimen. Specimen margins were classified either as 
positive or as negative using the criteria established in the training set. A margin was 
considered positive if there was evidence of tumor cells or tissue either at the immediate 
surface, or within the imaging depth of OCT (1-2 mm). Eleven tissue margins were identified 
as positive and 9 as negative with OCT analysis. Analysis of the corresponding H&E-stained 
histological sections yielded 9 true positives, 9 true negatives, 2 false positives, and 0 false 
negatives, giving a sensitivity of 100% and specificity of 82% (Table 2.1). Overall accuracy 
of OCT was 90% with a positive predictive value and a negative predictive value of 82% and 
100%, respectively. Three representative cases from the study set are presented in Figure 2.3 
and Figure 2.4. The first patient (female, age 66) was diagnosed with DCIS via ultrasound-
guided core-needle biopsy with a 3.0 cm primary tumor. This case (Figure 2.3) demonstrates 
OCT assessment of a negative tumor margin, which consists primarily of large lipid-filled 
adipocytes with interweaving microvasculature. The small dark highly scattering point-like 
regions in the OCT image correspond to individual nuclei of adipocytes. Histological 
evaluation indicated that tumor cells were located more than 3 mm from the surface, 
confirming the OCT findings of a negative margin. 
A second patient (female, age 60), diagnosed with invasive papillary carcinoma via 
ultrasound-guided core-needle biopsy, had a 0.8 cm primary tumor removed by lumpectomy. 
A third patient (female, age 51) was diagnosed with poorly differentiated infiltrating ductal 
carcinoma and high-grade ductal carcinoma in situ with a 2.3 cm primary tumor. 
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Intraoperative OCT imaging of the margins (Figure 2.4) revealed suspicious regions with 
increased and heterogeneous scattering within 1 mm of the inked surface (Figure 2.4a, female, 
age 60, patient #2) and within 0.5 to 1.25 mm of the surface (Figure 2.4c, female, age 51, 
patient #3). The matching H&E stained histology sections for the OCT images shown in 
Figure 2.4a and Figure 2.4c are provided in Figure 2.4b and Figure 2.4d, respectively, and 
confirmed the diagnostic features observed. These sections contained small and highly 
scattering cells, which contributed to the increased contrast when compared to adjacent 
adipocytes. The increased scattering is from strong reflections from tightly packed cells, 
which provides the contrast observed in OCT. These results demonstrate distinct structural 
features identified with real-time intraoperative OCT on unstained tissue specimens that can 
be used to identify positive and negative margins without compromising the structural 
integrity of the specimens. 
 
 
Table 2.1: Intraoperative Tumor Margin Assessment (OCT vs. Histopathology). 
 
Histology 
(Positive) 
Histology 
(Negative) Total 
 
OCT 
(Positive) 
9 (TP) 2 (FP) 11 PPV = 82% 
OCT 
(Negative) 
0 (FN) 9 (TN) 9 NPV = 100% 
Total 9 11 20  
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Figure 2.3: Negative tumor margin. OCT (a) and corresponding H&E-stained histology (b) of 
normal breast tissue near the surface of a lumpectomy specimen. The large adipose cells with 
point-like scattering nuclei predominate in the OCT image, which also contains a region of 
microvasculature (arrows). Features found in the real-time intraoperative OCT image 
correspond well to those identified in the post-surgical paraffin-embedded histology section. 
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Figure 2.4: Positive tumor margins. OCT images (a, c) show a distinct heterogeneously 
scattering region (arrows) with small, highly scattering foci indicative of collections of tumor 
cells. These features clearly extend to both the surface (the surgical margin) in (a) and the left 
side (c) of the specimen, but also are evident below adipose tissue in (c). The OCT image in 
(a) was acquired with a coverslip over the surface to reduce back reflection artifacts, which 
appear as vertical lines in (c). Corresponding H&E-stained histology (b, d) images show 
corresponding features, confirming the presence of these positive margins. 
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This study presents the first intraoperative demonstration of OCT as a real-time, high 
resolution imaging technique for the microscopic assessment of breast tumor margins. By 
providing subsurface imaging capabilities 1-2 mm deep with micron-scale resolution, OCT 
provides surgeons with the ability to assess margin status in real-time, complement current 
gross visual examination, potentially reduce the number of positive / close margins discovered 
post-operatively, and thereby reduce the need for additional surgical procedures. In the 
current standard of care, pathologists perform microscopic margin assessment within 2 mm 
range of the tissue surface using FSA or PSA to determine the need for additional tissue 
removal. 
OCT identified areas of homogeneous adipocytes, suspicious regions with highly 
scattering and tightly packed cells, and heterogeneous scattering patterns as some of the key 
features used to classify margins as negative or positive, as verified by histopathology. The 
large relative cell size difference easily separates the identification of adipocytes from tumor 
cells and stromal tissue. Increased nuclear density and changes in chromatin texture are 
believed to be responsible for high levels of scattering observed from cancer cells [26, 27]. At 
later tumor stages, observed characteristics change from open to filled ducts and lobules, and 
to heterogeneous tumor masses. Focal regions of scatterers embedded in adipose tissue, as 
identified under OCT, indicated smaller clusters of tumor cells. More advanced stages of 
cancer were identified by areas of highly scattering tissue with irregular and heterogeneous 
patterns. Due to the increased sampling rate of tumor margins offered by OCT, we expect to 
identify an increased number of positive surgical margins not otherwise grossly identifiable 
and likely missed due to limited sampling of standard histopathological analysis. 
 54 
Surgical artifacts such as cauterized tissue and superficial blood are identified in OCT 
images as a contiguous layer of dark scatterers. These artifacts appear homogeneous in nature 
and are limited to the cut surface of the surgical margin rather than extending deep into the 
tissue. A relatively large pool of blood or cauterized tissue can limit the penetration depth of 
OCT due to high scattering. The imaging penetration depth with a bloody surface (Figure 
2.4b) is slightly diminished, compared to a cauterized surface (Figure 2.2c) where penetration 
depth drops off sharply with little to no features observed beyond the cauterized tissue. 
Intravascular blood in small vessels and capillaries makes up a relatively small percentage of 
the tissue volume and has a minimal impact on the OCT penetration depth. In cases with 
residual surface blood, saline has been used to rapidly irrigate the surface to regain OCT 
imaging depth. OCT has been demonstrated for in vivo intravascular applications in humans, 
where an OCT imaging catheter is fully immersed in blood and imaging is performed 
following a saline flush [28]. These surgical artifacts can be differentiated from intrinsic 
tissue properties, and can be quickly addressed without interfering with the ability of OCT to 
assess the margin. The presence of dyes such as methylene blue or lymphazurin, which are 
used to map lymph drainage for sentinel and axillary lymph node dissections, absorb in the 
spectral region below 700 nm (Figure 2.5). Therefore, the presence of these dyes does not 
affect OCT imaging since our system operates in the spectral region around 1300 nm.  
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Figure 2.5: Absorption spectra from water (H2O) [29], oxyhemoglobin (HbO2) [30], 
hemoglobin (Hb) [30], Ti:Sapphire Laser (800 nm lab bench-based OCT systems), SLD 
(1300 nm portable clinical OCT system), Methylene Blue [31], and Lymphazurin. 
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Recent advances in OCT technology have increased data acquisition speeds to 
200,000 axial scans per second or greater [32]. This could permit acquisition of 400 frames 
per second for a scan range of 10 mm and a lateral resolution of 35 µm. For a 1 cm2 area, 
imaging could be achieved in a few seconds while maintaining the full lateral resolution in 
both x and y directions. Novel computational algorithms such as Interferometric Synthetic 
Aperture Microscopy (ISAM) are being implemented for real-time OCT imaging, yielding 
spatially-invariant lateral resolution equivalent to that achieved at the focus of the beam [33]. 
These combined advances offer the potential to vastly increase data acquisition rates and 
resolution without sacrificing the large scan area and real-time capabilities of OCT. The 
significant increase in data volume and limited time to analyze and interpret image sets will 
increase the need for automated classification algorithms [34, 35].  
The differentiation of malignant (carcinoma) from benign (fibroadenoma) tumors is an 
ongoing research effort, as with many other biomedical imaging techniques. Stromal tissue, 
which makes up a larger percentage of breast tissue in younger patients, is primarily 
composed of connective tissue and favorably, is generally less scattering compared to tumor 
tissue [36]. Studies have shown that the optical refractive index does not differ greatly 
between stromal and tumor tissue [37]. Preliminary results from our laboratory have identified 
a promising combined method for distinguishing between the two tissue types by examining 
the power attenuation in the signal, the periodicity of the scattering profile, and the extracted 
refractive index information to aid in automated classification of OCT signals [35, 37, 38]. 
Differentiation between benign fibrocystic changes versus malignant lesions will be important 
in further clinical studies. Cysts are expected to be readily distinguished due to their relatively 
large size, thin membranes, and low amount of scatterers within the cyst. Early morphological 
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changes such as ductal hyperplasia or dysplasia, characterized by increased cell density and 
nuclear-to-cytoplasm ratio, are likely to exhibit increased scattering. Ongoing work to 
improve resolution and to extract distinct image features may be necessary for distinguishing 
these early changes. 
2.8 Conclusions 
This study demonstrates the potential of real-time intraoperative OCT for margin 
assessment from resected breast lumpectomy specimens. OCT acquires images in the same 
physical range as that used in histological analysis to classify surgical margins as positive, 
close (< 2mm), or negative. The development of faster scanning handheld probes for OCT 
will allow surgeons to rapidly scan the in situ tumor cavity wall in addition to the lumpectomy 
specimen margin, providing surgeons guidance on tissue removal. In situ OCT imaging would 
effectively double the sampling depth by evaluating depths up to 2 mm on the specimen and 
on the cavity wall. Further studies with even higher resolution, comprehensive volumetric 
imaging, and automated tissue type classification are expected to reveal additional unique 
features that can be used to further improve the identification of positive and negative margins 
intraoperatively with OCT. Intraoperative identification of positive margins will decrease the 
need for additional surgical procedures and potentially the rate of local recurrence in breast 
cancer patients. 
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CHAPTER 3 
OPTICAL COHERENCE TOMOGRAPHY IN LYMPH NODE ASSESSMENT 
3.1 Introduction 
3.1.1 Clinical Importance of Lymph Node Assessment 
Lymph nodes serve as the primary site for filtering, sequestering, and degrading 
foreign particles that travel through the lymphatic system. Lymph nodes are typically 
classified as normal, reactive, or metastatic. A reactive node and a metastatic node are both 
relatively enlarged in size as lymphocytes and macrophages are recruited to the node in 
response to the presence of foreign particles or abnormal cells. However, in a metastatic node, 
there is an increased presence and involvement of cancer cells in addition to the inflammatory 
response. When the lymphatic system becomes impaired due to the disruption of the 
lymphatic network, lymphatic obstruction develops, leading to the accumulation of lymph 
fluid or lymphedema. Currently, nearly 20% of the patients that undergo axillary lymph node 
dissection (ALND) suffer from these types of edema [1, 2]. In addition, a recent study 
reported that the presence of micrometastases in the axillary lymph nodes contributed to a 
decrease in the five-year survival rates for women with early breast cancer [3]. 
3.1.2 Mapping of Lymph Nodes 
In lymph node mapping, a radioactive tracer (technetium-99) and/or a dye (methylene 
blue) is injected near the site of the primary tumor prior to the surgery. The tracer and/or dye 
are allowed to circulate for several hours, after which the sentinel node(s) are located and 
resected during the lumpectomy or mastectomy procedure [4]. Other lymphatic mapping 
methods include standard X-ray and computed tomography (CT) in conjunction with contrast 
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agents, or fluorescence techniques using near-infrared (NIR) quantum dots [5, 6] or 
indocyanine green (ICG) dye [7], which provide better localization of the lymph node. Lymph 
nodes are typically only removed in order to stage disease progression using histopathological 
analysis. A positive sentinel node status will prompt surgeons to consider patients for axillary 
lymph node dissections, further node sampling via biopsies, or whole-body imaging to 
determine the extent of the metastatic spread of cancer. 
3.1.3 Current and Experimental Nodal Assessment Techniques 
The current standard of care for lymph node assessment is paraffin section 
histopathological analysis. No real-time intraoperative microscopic technique is currently 
being widely used for the assessment of lymph nodes. The use of frozen section 
histopathology of lymph nodes is also an accepted nodal assessment method, but often takes 
20-30 minutes to perform, lengthening the time the patient is under general anesthesia [8, 9]. 
Several other intraoperative techniques are currently under investigation including touch 
imprint cytology [10, 11], molecular marker assays [12], frozen section analysis [8, 9], and 
Fourier transform infrared micro-spectroscopy [13]. All of these techniques require the 
physical sectioning of the lymph node, leading to the physical destruction of the nodal 
structural integrity and cellular architecture in order to perform the molecular assay, staining, 
or probing protocols. The use of wide-field NIR fluorescence imaging has also been 
developed to better visualize the dynamics of the lymphatic system [14, 15]. Preliminary 
studies using a laboratory based OCT system centered at 800 nm on lymph nodes resected 
from a rat animal model and from a human head and neck lymph node demonstrated the 
ability for OCT to image the capsule and sub-capsular features of the lymph nodes [16]. 
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3.2 Portable Clinical Spectral-Domain Optical Coherence Tomography System 
A clinical spectral-domain OCT (SD-OCT) system [31], previously described in 
Chapters 1 and 2, was used to assess sentinel lymph nodes for this feasibility imaging study. 
The OCT system uses an SLD centered at 1310 nm with a bandwidth of 92 nm. The system 
has a transverse resolution of 35.0 µm with a confocal parameter of 1.47 mm. The broad 
bandwidth of the optical light source resulted in an axial resolution of 8.2 µm in air or 5.9 µm 
in tissue. The penetration depth of OCT imaging in human axillary lymph nodes was 1-2 mm. 
A commercial OCT system (Bioptigen, Inc., Research Triangle Park, NC) with similar 
instrument specifications and performance parameters as the custom built system described 
previously was also used for this study. Both systems used light sources centered at 1310 nm 
with a bandwidth of 90-100 nm, used the same detection system, and had similar optical 
elements in the sample arm yielding comparable axial and transverse resolutions. The main 
difference between the two systems was the beam scanning mechanism, which enabled the 
custom-built system to scan over longer lateral distances (10 mm) to produce                     
two-dimensional images, while the commercial system was able to scan over a 5x5 mm 
region to produce three-dimensional volumetric images. The acquisition times were ~25 
seconds for a single two-dimensional image (10 mm) for the custom-built system and ~25 
seconds for a full three-dimensional volumetric block of images (5 mm x 5 mm) for the 
commercial OCT system.  
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3.3 Clinical Study 
The patients identified and recruited for this study had primary breast tumors (invasive 
and/or in situ carcinoma) in need of surgical resection, and/or in need of sentinel lymph node 
dissection, as determined by their physicians at Carle Foundation Hospital and Carle Clinic 
Association, Urbana, Illinois, based on previous radiological films, biopsy results, and other 
relevant diagnostic information. Patients were consented prior to each surgery based on the 
approved protocols from the institutional review boards (IRB) at the University of Illinois at 
Urbana-Champaign and Carle Foundation Hospital. After resection of the sentinel and/or 
axillary lymph node(s) by the surgeon, and prior to microscopic assessment by the 
pathologist, the lymph node was imaged in the operating room using the clinical OCT system. 
Of the lymph nodes resected during each procedure, one sentinel lymph node, as determined 
by the surgeon, was imaged per patient for this feasibility study. In cases with multiple 
sentinel lymph nodes, only the first resected sentinel node was chosen and imaged. No 
additional nodes were imaged, due to time constraints, and no other criteria were used in 
determining which lymph node would be imaged. In cases where the sentinel lymph node 
could not be clearly distinguished from other resected lymph nodes, the first axillary lymph 
node excised was imaged. The intact outer capsule of the sentinel lymph node was exposed 
for imaging without affecting the structural integrity of the tissue specimen. The OCT beam 
was laterally scanned across the node over a 10 mm distance to produce a two-dimensional 
cross-sectional OCT image. Subsequently, multiple parallel OCT images (spaced 1 mm apart) 
were acquired orthogonal to the long axis of the node. In cases where the commercial OCT 
system was used, 5x5 mm blocks of images were acquired covering the entire node. Upon 
completion of the imaging session, the sentinel node was returned to the surgical staff for 
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standard specimen processing, and transported to the pathology department for sectioning, 
staining, and histopathological analysis. 
3.3.1 Specimen Information 
A total of 30 sentinel lymph nodes and an additional 106 axillary lymph nodes were 
surgically resected from 17 patients as determined by the surgeons as part of the standard of 
care. A subset (16 sentinel, 1 axillary) of the lymph nodes (1 per patient) chosen, based on the 
order they were resected, were imaged with OCT intraoperatively. Of all the nodes resected, 
11 (8%) were metastatic and even fewer, 2 (1%), were reactive, resulting in 91% of all nodes 
resected being classified as normal. When considering only the sentinel lymph nodes as 
labeled by the surgeons, 4/30 (13%) sentinel lymph nodes and 1/30 (3%) were classified as 
metastatic and reactive, respectively, by histopathological analysis, resulting in 84% of the 
sentinel nodes being reported as normal. 
OCT images of 17 lymph nodes from 17 patients were used to identify unique image 
features that could potentially be used to classify lymph nodes as normal, reactive, or 
metastatic. OCT images were acquired from 16 of the 30 sentinel lymph nodes from 16 
patients, and 1 axillary lymph node from the 17th patient, where identification of the sentinel 
node was not possible by the surgeon. Of the 17 nodes imaged with OCT, histopathological 
analysis classified 3 nodes as metastatic, 1 node as reactive, and the remaining 13 nodes as 
normal. OCT images from two of the three metastatic nodes were excluded from the study 
because they could not be adequately interpreted due to poor exposure of the node capsule 
from the surrounding fatty tissue, which placed the nodal architectural features beyond the 
imaging depth of OCT. The third metastatic node was imaged using a commercial OCT 
system. 
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3.4 OCT Image Processing & Evaluation Protocol 
OCT images were standardized by subtracting the background power spectrum from 
the raw data, resampling the data using the cubic spline interpolation technique, and 
displaying the images on the same intensity scale to account for day-to-day system variations. 
The background power spectrum was determined by acquiring an image with the sample arm 
blocked and recording the power spectrum of the light reflected in the reference arm. This 
process removes image artifacts that are inherent to the OCT system at the time of imaging. 
Fifteen patients were enrolled as part of this study to evaluate the potential of OCT imaging 
for real-time intraoperative assessment of lymph nodes using the custom-built system. An 
additional two patients were enrolled to evaluate the commercial OCT system and the 
advantages of three-dimensional volumetric data acquisition. OCT images were evaluated by 
a single interpreter intraoperatively, allowing for consistent identification of suspicious areas 
based on the level and distribution of scattering intensity in the outer layers and cortex of the 
nodes, and the ability to distinguish the boundary between the capsule and cortex of the 
nodes. Since nodal status is not currently determined intraoperatively by surgeons but rather 
post-operatively by pathologists, no information about the nodes was transmitted between the 
surgeons or surgical staff, and the researcher imaging and evaluating the OCT images. Using 
these image features, a single researcher in a single setting evaluated and classified OCT 
images into normal and abnormal categories where both metastatic and reactive nodes were 
considered abnormal nodes. 
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3.5 Histopathological Image Evaluation Protocol 
According to the standard of care, the sentinel lymph node was bisected, paraffin 
embedded, and sectioned for histopathological analysis in the pathology department. The 
tissue sections were H&E stained and in some cases also stained immunohistochemically for 
cytokeratin 7 (CK7) to further confirm the presence of and characterize the cancer cells in the 
sentinel node originated from the breast. The histology slides were digitized using a light 
microscope (BH-2, Olympus, Inc., Center Valley, PA) at 4X magnification and autostitched 
together (Adobe Photoshop CS3) to provide a single montage for viewing and comparison 
purposes. The H&E stained histology slides were reviewed by board-certified pathologists at 
Carle Foundation Hospital (Urbana, IL) and classified as normal, reactive, or metastatic. The 
histopathological processing and analysis were performed as part of the standard of care and 
reported by the pathology department at Carle Foundation Hospital (Urbana, IL). 
3.6 OCT Images of Normal, Reactive, and Metastatic Lymph Nodes 
Representative intraoperative images from normal (Figure 3.1 and Figure 3.3), 
reactive (Figure 3.2), and metastatic (Figure 3.4) axillary lymph nodes are shown. In the 
normal lymph nodes (Figure 3.1 and Figure 3.3), there is a distinct highly scattering capsule 
present, in comparison to the lower scattering cortex. The transverse sinuses separating the 
lymphoid follicles of the lymph node can be observed by OCT in Figure 3.3. The 
corresponding H&E stained histological slides show normal nodes with expected architecture 
that are either largely lipid filled (Figure 3.1) or contain more eosinophilic (pink) structures 
indicative of the presence of intracellular and extracellular proteins (Figure 3.3). The sub-
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capsular sinus separates the capsule from the cortex, and is organized into discrete lymphoid 
nodules with germinal centers observable in normal lymph nodes. The distinct boundary 
between the capsule and the cortex is no longer visible in reactive (Figure 3.2) and metastatic 
(Figure 3.4) nodes where the entire node becomes more highly scattering, matching the 
scattering intensity level from the capsule, forming a single homogeneous scattering layer. 
The corresponding H&E histology slides presented in Figure 3.2 and Figure 3.4 have 
more basophilic structures as exhibited by darker blue staining specific to nucleic acids found 
in ribosomes, chromatin in the nucleus, and RNA in the cytoplasm. The metastatic lymph 
node shows a loss of normal tissue architecture as there is an obvious lymphoid depletion 
characterized by a decrease in the number and size of follicles with some or no germinal 
centers. At the same time, the decrease of sinus spaces and increased density of cells observed 
is due to the high level of cancer cell proliferation. 
Three-dimensional OCT reconstructions are presented in Figure 3.3 and Figure 3.4, 
demonstrating the added level of details available through the reconstructions. These 
renderings identify the same features as those found in the two-dimensional images but 
further allows for the arbitrary optical sectioning of the tissue along planes that are not 
necessarily the same as the OCT imaging acquisition planes. These intraoperative findings 
from human lymph nodes extend our observations from previously reported OCT image data 
of lymph nodes from a rat mammary model [16]. The normal rat lymph node exhibited a 
highly scattering layer that correspond to the capsule, compared to the low scattering areas 
which are more representative of the lymph node cortex [16]. In the same report, OCT images 
from a necrotic metastatic lymph node exhibited a high level of scattering intensity and 
capsule disruption.  
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Figure 3.1: Normal Lymph Node. OCT images from a normal sentinel lymph node (left) with 
corresponding H&E histology (right) demonstrate an intact capsule structure that is easily 
distinguishable from the cortex of the lymph node. The OCT images are highlighted (orange 
boxes) with the regions that correlate with the histology images.  
  73 
 
 
 
 
 
Figure 3.2: Reactive Lymph Node. OCT image from a reactive axillary lymph node (top) with 
corresponding H&E histology (bottom). In this case, increased cellular density in the cortex, 
representative of a reactive lymph node, contributed to an increased scattering signal observed 
under OCT. The change in scattering intensity in the cortex begins to match the scattering 
intensity of the capsule, decreasing the ability to distinguish the capsule from the cortex under 
the OCT images (arrows).  
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Figure 3.3: Three-dimensional rendering of a normal lymph node. OCT image volume 
acquired from a normal sentinel lymph node (left) is shown with the corresponding H&E 
histology (right). The normal lymph node presents a clear capsule that is easily differentiated 
from the low-scattering cortex. The OCT images correlate to regions in the histology sections 
that are highlighted by red boxes. The OCT image block measures 5 x 5 x 1.7 mm.  
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Figure 3.4: Three-dimensional rendering of a metastatic lymph node. OCT image volume 
acquired from a metastatic axillary lymph node (left) in a single session is shown with the 
corresponding H&E histology (right). As with reactive lymph nodes, increased scattering 
from the node is observed in the OCT data, and the ability to differentiate distinct boundaries 
between the node capsule and cortex has been lost. The OCT images correlate to regions in 
the histology sections that are highlighted by red boxes. The OCT image block measures 5 x 5 
x 1.7 mm.  
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The relatively high percentage of normal nodes resected during lymph node dissection 
procedures, as was evidenced in the patients enrolled in this study, points to the significant 
need for a real-time intraoperative microscopic nodal assessment technology. OCT has the 
potential to fill this crucial role by providing real-time intraoperative information through the 
identification of unique architectural features observed in the capsule and outer cortex of the 
lymph node. These features correspond to known morphological changes in reactive and 
metastatic lymph nodes, and all are accessible within the penetration depth of OCT. 
3.6.1 Identification of Normal Nodes from Reactive and Metastatic Lymph Nodes 
When cancer cells metastasize through the lymphatic system, the nodes serve as the 
primary line of defense to sequester the cancer cells and initiate a tumor-specific 
immunological response. This process will initially cause an enlargement of the lymph node 
as part of the reactive inflammatory response, but this enlargement can also be attributed to 
the replication of cancer cells in the nodes. The presence of inflammation in the node, 
however, does not sufficiently indicate the presence of cancer cells. Hypercellularity of the 
lymph node, either due to the inflammatory response or the replication and expansion of 
cancer cells, not only increases the relative size of the node but also increases the cellular 
density within the node. These changes typically correspond to an increase in scattering 
observed in OCT, and match the scattering levels observed in the capsule. As the scattering 
intensity in the capsule and cortex areas become similar, the differentiation of the capsule 
from the cortex becomes less distinct. Increased changes in scattering observed in the cortex 
of reactive and metastatic nodes are more likely due to increased cellular density, but could 
also be attributed to an increased number of cancer cells which have a higher N/C ratio. These 
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changes are more predominant in the cortex region where the germinal centers and follicles, 
the primary sites of lymphocyte recruitment and aggregation, are located. 
3.6.2 Potential Clinical Impact 
A large majority of the lymph nodes resected for breast cancer staging are negative 
normal lymph nodes. In addition, the major purpose for resecting the lymph nodes has been 
largely for the staging of the disease and not the management or treatment of the disease. In 
addition, the primary surgical risk factors for lymphedema are nodal dissection of the axillary 
lymph nodes, as well as associated scarring from surgical intervention. Therefore, reducing 
the number or eliminating the need to resect normal nodes during surgery may not only 
reduce the number of lymph nodes resected, but also decrease the risk of developing 
lymphedema. With a 1-2 mm imaging penetration depth, OCT is a suitable modality for 
visualizing the microscopic lymph node architecture, including the capsule and the outer 
cortex containing the follicles and germinal centers. In normal nodes, OCT is capable of 
clearly defining the boundary between the capsule and the cortex based on scattering 
intensities; this boundary is lost in abnormal lymph nodes. While there is currently no suitable 
real-time intraoperative method to assess the lymph node prior to its surgical resection, OCT 
would fill this niche by providing high-resolution microscopic images in real time. 
Histopathological analysis from paraffin sections, the current standard of care, is unable to 
provide surgeons with real-time information on the nodal status that could be used to guide 
the surgical resection of lymph nodes. OCT is capable of providing this information 
intraoperatively in real time, with the potential for in vivo or in situ imaging, thereby 
potentially eliminating the need for further lymph node resections and reducing the number of 
resulting complications. 
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3.7 Conclusions 
The intraoperative OCT imaging data from the lymph nodes in this feasibility study 
demonstrate promising results. Distinct morphological differences were observed in OCT 
images between defined classifications of lymph nodes, and they correlated strongly with 
corresponding histopathological findings within the penetration depth of the OCT imaging 
system. These initial studies demonstrate that the relevant diagnostic information needed to 
classify lymph nodes is accessible by OCT from outside the lymph node capsule, leaving the 
lymph node structurally intact. Trans-capsule imaging by OCT, along with the 
implementation of a fast scanning handheld probe [17], will allow rapid in situ imaging of 
lymph nodes. Needle-based OCT imaging probes would allow further minimally-invasive 
probing of nodes that are not fully exposed or easily accessible, particularly for 
transcutaneous needle-biopsy procedures of lymph nodes [18-20]. 
Future in vivo studies will further determine the clinical impact of OCT on reducing 
the number of normal lymph nodes removed and the subsequent rate of morbid complications 
associated with lymph node dissections and breast cancer surgeries. The implementation of 
recent technological advances to further increase the resolution of OCT [21] and data 
acquisition speed [22], and to computationally classify tissue types [18, 23], will improve the 
usability and effectiveness of OCT in the intraoperative assessment of lymph nodes by 
enhancing the capability to examine the underlying lymph node micro-architecture, by 
rendering three-dimensional OCT data sets for multi-sectional assessment, and by rapidly 
classifying features and tissue types using computer-aided detection.  
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CHAPTER 4 
PROTEIN MICROSPHERES 
4.1 Introduction 
Optical coherence tomography has been shown to have great potential as an 
optical imaging technique for assessing cancer [1-5]. It has also been well studied for 
cardiovascular applications and is currently being widely used as part of a standard of 
care in the field of ophthalmology [6]. OCT provides micron-scale resolution images at 
depths of 1-3 mm beneath the sample surface for highly scattering tissues. However, 
OCT is largely limited by only providing structural information about the sample. In the 
detection and diagnosis of diseases, the earlier that disease can be detected, the earlier it 
can be treated, and the higher the success rate for treatment and recovery. To further 
increase the utility of OCT in biomedical applications, it would be beneficial to extend or 
compliment structural OCT with the development of functional modalities of OCT, the 
development of contrast agents, or integrating OCT as part of a multi-modal imaging 
system to detect changes in the tissue before morphological changes become readily 
apparent under structural OCT. 
Various functional modalities of OCT have been developed over the last several 
years including spectroscopic OCT (S-OCT) [7-12], pump-probe OCT [13-16], 
polarization-sensitive OCT (PS-OCT) [17-28], and magnetomotive OCT (MM-OCT) 
[29-35] to move OCT into the molecular imaging domain. The utility of these techniques 
is greatly enhanced when combined with exogenous contrast agents compared to relying 
only on the tissues’ endogenous contrast. In addition, the use of contrast agents can also 
provide either nonspecific or targeted contrast to the sample. Research in biomedical 
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imaging is transitioning from the development of individual imaging modalities as the 
technology matures to more emphasis on the development of complimentary contrast 
agents or the development of multi-modal imaging systems combining the strengths of 
multiple techniques. 
The utility of OCT can be extended through the addition of targeted contrast 
agents by visualizing structures or molecular changes not readily visible under structural 
OCT. Contrast agents have been widely developed to complement the capabilities of 
imaging modalities by providing nonspecific contrast to images or by providing targeted 
contrast to better highlight areas of interest. The exogenous contrast can be overlaid on 
top of the endogenous contrast from OCT and combines the molecular sensitivity of 
targeted contrast agents with the micron-scale resolution structural imaging of OCT. 
In the field of biomedical optics, there is a great need to combine wide field 
imaging modalities with microscopic imaging modalities. A limitation of optical 
techniques such as OCT, Raman spectroscopy, fluorescence spectroscopy, or reflectance 
techniques is the relatively limited field of view. A compromise must be made to balance 
the advantages of high resolution microscopic imaging made possible by optical imaging 
methods and the practical need to sample over large fields of view in a clinical setting. 
This balance is more critical at earlier disease stages when lesions are not physically 
palpable or visible to the human eye. To overcome this balancing act, different imaging 
modalities can be combined to better guide microscopic imaging and to increase the 
overall detection sensitivity and specificity of the disease. In this scenario, the use of 
multi-modal contrast agents detectable by both wide field (magnetic resonance imaging, 
ultrasound imaging, or fluorescence imaging) and microscopic imaging modalities (OCT, 
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MM-OCT, fluorescence microscopy) are highly beneficial for targeted localization of 
sites of interest and allow improved co-registration of the imaging data across imaging 
modalities. 
Contrast agents for OCT can be categorized by various design strategies. The 
simplest design strategy is to directly increase the backscattering in the tissue by 
introducing strongly scattering particles. The presence of these particles should change 
the effective refractive index of the targeted local microenvironment compared to the 
neighboring non-targeted areas. The inability to differentiate between exogenous 
scattering of the contrast agents and endogenous scattering of the tissue specimen is a 
limitation of this method especially in applications where taking an OCT image prior to 
the introduction of contrast agents may not be possible. This strategy is most 
advantageous for the non-specific increase in the contrast of low scattering tissues and 
samples. When using targeted scattering contrast agents, the endogenous contrast should 
be well characterized to study the increased contrast from the scattering agents. 
The ideal strategy for designing a contrast agent begins with a particle that can 
serve as the construct or vehicle. The particle can then be modified with different 
nanoparticles that are individually optimized for each imaging modality of interest. This 
flexible framework for designing a multi-modal contrast agent by incorporating 
nanoparticles that are specific to each imaging modality is more advantageous than the 
development of a single nanoparticle that could be detected under multiple imaging 
modalities. In this thesis, protein microspheres serve as a novel vehicle that couples a 
diverse array of nanoparticle-based contrast agents for multiple imaging modalities. 
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Various nanoparticles that provide scattering, fluorescent, and/or magnetic contrast can 
be encapsulated into the inner core of the microspheres or embedded in the protein shell. 
The utility of the microsphere design as an encapsulation vehicle can be extended 
beyond contrast agents to function as a targeted therapeutic delivery method. The surface 
of the protein microspheres can be functionalized using a layer-by-layer (LBL) adhesion 
method described in this chapter and in more detail in Chapter 5. Surface-functionalized 
microspheres encapsulated with hydrophobic drugs such as paclitaxel could provide a 
targeted cellular method for killing single cells, by which therapeutic agents could be 
released into the cell cytoplasm upon cellular uptake of the microsphere. Furthermore, the 
microspheres could be externally controlled by magnetic fields or ultrasound waves to 
trigger their potential rupture or controlled release of their contents into the local 
vasculature or extracellular matrix of the targeted area. Lastly, the surface-functionalized 
microspheres could be encapsulated with heat-absorbing particles to induce targeted 
hyperthermia. Through these potential therapeutic strategies, protein microspheres could 
fill a critical need for the targeted treatment of diseases. 
4.2 Protein Microspheres 
The modified oil-filled protein microspheres presented in this thesis were initially 
developed in Prof. Suslick lab at the University of Illinois at Urbana-Champaign [36, 37]. 
These microspheres are sonochemically synthesized using high-frequency ultrasound. 
The sonication process creates a fluid mixing state during the emulsification process, 
forming a protein shell that encapsulates the oil and hydrophobic nanoparticles. 
Traditionally, these microspheres are-filed with air or perfluorocarbon for use as 
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ultrasound contrast agents. Replacing the inner core with vegetable oil instead of a gas 
renders these microspheres much more stable, less likely to rupture, and extending their 
lifetimes from several days to several months when compared to their gas-filed 
counterparts [36, 38]. 
The size of the microspheres can vary from 200 nm to 15 µm in diameter [36]. 
According to previous reports, the most important factor in determining the size of the 
microsphere is the surface tension between the oil and protein layers at the time of 
synthesis [38-40]. The use of surfactants were previously reported to alter the surface 
tension between these layers and produce microspheres as small as 200-400 nm [38, 39]. 
In addition to surfactants, the concentration of bovine serum albumin (BSA) used to 
synthesize the microspheres can be increased to reduce the size of the microspheres [38]. 
Increasing the concentration of BSA increased the formation of partially cross-linked 
BSA aggregates in solution. Increasing both the sonication frequency and the acoustic 
power also had a large effect in increasing the resulting yield of microspheres, but had 
little impact on the resulting size distribution of the protein microspheres [38]. 
In previously reported studies, protein microspheres were initially modified to 
provide added contrast for OCT by incorporating scattering nanoparticles. These earlier 
experiments demonstrated that the effective refractive index of the protein microspheres 
can be altered by modifying the inner core or shell with nanoparticles that have refractive 
indices that are different (e.g. gold, RI = 0.18, or carbon, RI = 3.08) compared to tissue 
(RI = 1.48) [36, 38]. This differential in refractive index provides an increased 
backscattering of light from the sample and thus increases the ability to see more 
structures where the microspheres are located. These same microspheres have been 
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synthesized to encapsulate the iron oxide in the inner core providing contrast for 
magnetic resonance imaging (MRI) and magnetomotive optical coherence tomography 
(MM-OCT) [33, 38-40]. Encapsulation of various dyes, which absorb / emit in the visible 
and near infrared regions, has also been used for fluorescence applications [38, 39]. 
The protein microspheres presented in this thesis were designed and optimized 
primarily to provide enhanced contrast under wide-field fluorescence imaging, magnetic 
resonance imaging, MM-OCT, and fluorescence microscopy with the goal of in vivo 
targeting of these microspheres to tumors. The protein microspheres encapsulated iron 
oxide, Nile Red dye, and DiR dye. In designing the protein microspheres as a contrast 
agent for MM-OCT and OCT, the microspheres were initially tested to ensure that they 
could provide sufficient added contrast above the endogenous OCT contrast [33]. 
Although strong scatterers are advantageous for detection by OCT, a sample that is too 
strongly scattering will severely limit the OCT penetration depth, as was apparent in 
imaging strongly scattering tissues such as tumors. The design and development of 
protein microspheres as a contrast agent will be described in greater detail in Chapter 5. 
This chapter focuses on the synthesis of protein microspheres and encapsulation of 
contrast particles, the visual characterization of the microspheres through scanning 
electron microscopy and transmission electron microscopy, and the effects of the 
encapsulating particles on the size distribution of the protein microspheres. 
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Figure 4.1: Representation of the protein microsphere as a targeted multi-modal contrast 
agent. The inner oil core (blue) contains the hydrophobic contrast agents such as 
fluorescent dyes (Nile Red or DiR) and magnetic particles (iron oxide). The boundary 
between the blue and green layers represents the BSA protein shell. The PDDA (yellow 
dots) is layered to reverse the surface charge of the microspheres. The silica is layered 
(blue dots) on top of the PDDA layer. The RGD poly-lysine sequence is layered (black 
lines) on top of the silica layer with the poly-lysine sequence end adhering to the silica 
and the exposed RGD sequence end to the surroundings to target the protein microsphere 
to the integrin receptor. 
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4.3 Protein Microsphere Synthesis 
The structure of the protein microsphere is composed of three main 
compartments: the inner hydrophobic core, the outer hydrophilic protein shell, and the 
surface of the shell. Each of these components can incorporate a varying number of 
particles to provide contrast or add functionality to the protein microspheres. The 
versatility of the protein microsphere to incorporate a wide variety of dyes, nanoparticles, 
and ligands makes it an ideal construct for biomedical applications. By being able to 
combine multiple contrast mechanisms into a single vehicle, the protein microsphere can 
provide simultaneous contrast under a wide field imaging modality (such as magnetic 
resonance imaging, ultrasound, or fluorescence imaging) and a microscopic imaging 
modality (such as optical coherence tomography, or other spectroscopic techniques). 
Particles that are more hydrophilic or not as easily miscible into the oil can be suspended 
into the BSA protein layer and become embedded into the protein shell. Lastly, the 
microspheres can be targeted with ligands on the shell surface using the layer-by-layer 
adhesion method. In addition to in vivo targeting of the microspheres, cellular binding of 
the microspheres via these ligands can be used to probe cell mechanics and dynamics.  
In order to modify the content of the inner oil core, the particles must be miscible 
in vegetable oil. Typically particles are first suspended in a solvent prior to being placed 
into the oil suspension. For example, iron oxide and Nile Red are initially dissolved in 
hexane, while DiR is dissolved in 100% ethanol (200 proof) and bubbled with nitrogen. 
Similarly, to modify the composition of the outer protein shell, the particles of interest 
must be hydrophilic and thoroughly suspended into the 5% BSA protein solution. The 
outer protein shell measures approximately 50 nm in thickness [36], and when compared 
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to the volume of the inner core, the loading capacity of particles into the shell is relatively 
much lower than the encapsulated particles in the oil core. Although this has not yet been 
well studied, it is conceivable that having too many particles incorporated into the protein 
shell could have several effects on the characteristics and stability of the synthesized 
microspheres. The type, concentration, and size of particles used, as well as the ability for 
the BSA protein to form shells and crosslink, could hinder microsphere synthesis by 
decreasing the overall stability of the protein microspheres. The addition of these 
particles and/or solvents into either the oil or protein solution could alter the surface 
tension between the two layers. The change in surface tension could alter the resulting 
size distribution of the protein microspheres. 
The synthesis of protein microspheres depends on three primary concepts: the 
emulsification process, the aggregation of protein at the oil / water interface, and the 
chemical crosslinking of protein. In the case of BSA protein, crosslinking occurs via the 
formation of disulfide bonds through inter-protein cysteine oxidation. The detailed 
methods for synthesizing protein microspheres with encapsulated iron oxide 
nanoparticles, Nile Red fluorescent dye, or DiR fluorescent dye in an oil core will be 
described. For the studies presented in this thesis, the outer protein shell was not altered 
and only consisted of BSA. Lastly, the microsphere surface was functionalized by adding 
layers of polydimethyl diallyl chloride (PDDA), followed by silica, and then followed by 
an Arginine-Glycine-Aspartic Acid peptide sequence attached to a poly-lysine sequence 
(linear sequence of amino acids, RGDKKKKKK) using the layer-by-layer method. 
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4.3.1 Encapsulation of Particles in the Oil Core of the Protein Microspheres 
Many different types of particles have been previously encapsulated into the oil 
core of protein microspheres. Lee, et. al., were successful at synthesizing scattering 
microspheres that encapsulated melanin, gold, or carbon [36]. Toublan demonstrated the 
encapsulation of bodipy dye, Nile Red dye, heptamethylcyanine NIR dye, and iron oxide 
nanoparticles [38]. The feasibility of incorporating a wide variety of materials into the oil 
core makes protein microspheres an ideal vehicle that could serve not only as a contrast 
agent but also as a therapeutic agent. The main challenge for incorporating particles into 
the inner core of the microspheres is the ability to dissolve them into the vegetable oil. 
To synthesize the protein microcapsules, iron oxide (Sigma Aldrich, 544884-25G) 
was initially dissolved into hexane at a concentration of 250 mg of iron oxide / 2 mL of 
hexane. The iron oxide must be well dissolved into the hexane prior to mixing with 
vegetable oil. Additional hexane may be added or the solution may be placed in a 
sonicator for at least 15 mins to expedite this process. Once well dissolved, the solution 
was resuspended into the vegetable oil at a concentration of 50 mg of iron oxide to 1 mL 
of vegetable oil. Studies presented in this thesis will demonstrate that there was an upper 
limit to the amount of iron oxide that could be encapsulated into the protein 
microspheres. The solution was sonicated for an additional 30 mins or until it was well 
dissolved. 
The Nile Red dye oil solution was prepared in a similar fashion to the iron oxide 
oil solution. It was dissolved into hexane at a concentration of 2.5 mg of Nile Red / 1 mL 
of hexane. After sonication for at least 15 mins, the Nile Red solution was resuspended 
into the oil solution at a concentration of 0.5 mg of Nile Red to 1 mL of vegetable oil. 
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The solution was sonicated for an additional 30 mins or until the solution was well 
dissolved. 
The DiR dye (AAT Bioquest, 22070) was dissolved into 100% or 200 proof 
ethanol at a concentration of 25 mg (1 vial) to 5 mL of ethanol. It is important to note that 
the DiR solution should not be placed into the sonicator, exposed to heat, or exposed to 
light. The DiR dye in its pure form is highly sensitive to heat and light and was stored at  
-80°C in the dark. Once dissolved into 100% ethanol, the DiR solution was immediately 
mixed into the vegetable oil at a concentration of 5 mg of DiR to 1 mL of vegetable oil. 
The solution was quickly vortexed to ensure that it was well mixed. 
Synthesis of the oil solutions was prepared in amber-colored glass vials to protect 
the fluorophores from exposure to light. Glass vials were used instead of plastic conical 
vials because the oil solutions were later placed into a water bath to evaporate the 
solvents that initially suspended the nanoparticles. Depending on the temperatures used, 
the plastic conical vials could melt or react with the oil solution itself. 
For solutions containing iron oxide and/or Nile Red, the oil solutions were placed 
in a water bath set to 80-100°C in a chemical fume hood in order to evaporate hexane. 
For solutions containing DiR dye, the water bath temperature was set at no higher than 
55°C in a chemical fume hood in order to evaporate ethanol. The fluorescent properties 
of DiR can quickly deteriorate at temperatures higher than 55°C, and this was evidenced 
by a color change from a bright green to a yellow-orange solution. In addition to the 
requirement for a lower water bath temperature, nitrogen gas must be bubbled through 
the DiR oil solution during the evaporation of ethanol. This also helped preserve the 
fluorescent properties of the DiR dye. It takes 1-2 hrs for the hexane to evaporate from 
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the iron oxide or Nile Red oil stock solutions and 30 mins for the ethanol to evaporate 
from the DiR oil stock solution. Once the solvents (hexane or ethanol) were evaporated, 
the oil stock solutions could be kept for extended periods (months) on a rotisserie rotator 
in the fridge at 0°C. The DiR oil stock solution was kept frozen at -20°C. 
4.3.2 Embedding Particles in the Protein Shell of the Microspheres 
The protein shell of the microspheres was comprised of bovine serum albumin 
(BSA). A 5% (by weight) BSA solution was made using BSA (Sigma, A7030-50G) and 
nanopure water. A pH level of the solution around 7.4 was necessary for successful layer-
by-layer adhesion on the microsphere surface. In order to embed particles into the outer 
protein shell of microspheres, the particles can first be suspended in a solvent or polymer 
that makes it more miscible into the hydrophilic BSA solution. Toublan, et. al., used this 
method to embed colloids of gold nanoparticles into the protein shell because 
encapsulating the gold nanoparticles into the oil core was too challenging [38].  
4.3.3 Emulsification of the Protein Microspheres 
Once all of the solutions were prepared, 4 mL of the BSA solution was aliquoted 
into the bottom of the Suslick reaction vessel (Figure 4.2). The Suslick reaction vessel 
was mounted into the collar around the ultrasonic horn. The tip of the ultrasonic horn was 
slightly submerged in the BSA layer. One milliliter of any particular oil solution 
containing the desired particles for encapsulation was added to the reaction vessel 
through one of the three inlets, forming a continuous layer of oil solution on top of the 
BSA layer. Deviations from an 80:20 ratio of protein to oil can be used as long as the 
final level of the oil-protein interface was at the tip of the ultrasonic horn. 
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Figure 4.2: Setup for the sonochemical synthesis of microspheres. The Suslick reaction 
vessel containing an emulsion of the oil layer (top layer) and the protein layer (bottom 
layer) was mounted into a collar around an ultrasonic titanium horn oriented upright to 
the reaction vessel. The tip of the ultrasonic horn was optimally placed at the oil-protein 
interface [38-40]. (Courtesy of Prof. Kenneth Suslick’s group) 
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The reaction vessel was lowered into a 45°C water bath. This temperature was 
previously reported to provide the maximum energy for the radical formation without 
reaching a temperature above 60°C during the sonochemical process [39]. Since proteins 
denature at temperatures above 65°C, it was critical to monitor the temperature. The 
solution was emulsified using an ultrasonic horn with a tip size of 1 cm at a frequency of 
20 KHz and an acoustic power of 35 Watts/cm2 (amplitude set at 70%) for three mins. 
4.3.4 Protein Microsphere Washing and Purification 
The resulting solution was resuspended in cold phosphate buffered saline (PBS, 
pH 7.0) to a volume of 12 mL in a 15 mL conical vial. A 500 mL solution of PBS was 
prepared with 500 mL of nanopure water, 2.98 g of NaCl, and 6.85 g KH2PO4. The pH of 
the PBS was adjusted to a pH of 7 using KOH pellets (~15-16 pellets). The microsphere 
solution at this stage were filtered based on size to remove particles greater than 5 µm, 
although this was generally not necessary because the microspheres synthesized using 
this particular protocol were already under 5 µm according to size distribution 
measurements. The microsphere solutions were equally divided into twelve 1.5 mL 
Eppendorf tubes and centrifuged at 0°C for 6 mins at 3500 RPM. Once centrifuged, the 
microspheres separated into a top layer while the aqueous solution was on the bottom. 
The microsphere layer was pierced using a glass pipette, and the bottom layer was 
removed. At this point, the twelve Eppendorf tubes of microspheres were consolidated 
into no less than three Eppendorf tubes. The microspheres were washed using ice cold 
PBS and resuspended using plastic transfer pipettes. Plastic transfer pipettes were used 
because microspheres had a tendency to stick to the sides of glass pipettes, resulting in a 
higher loss of sample. Care was taken to avoid agitating microsphere solutions by 
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vortexing or pipetting up and down, as these techniques increased aggregation of 
microspheres. Once resuspended in PBS, the microspheres were centrifuged for 5 mins at 
6000 RPM. These centrifugal washes were repeated until the bottom aqueous layer 
became clear. Once the microspheres were washed, they could be stored for several 
months in a 4°C refrigerator. Microspheres should not be kept constantly rotating on a 
rotisserie rotator or shaken long term once the LBL procedure has been completed. This 
constant motion and force exerted as the microspheres swing from one end of the 
Eppendorf tube to the other end decreases their stability and can cause them to leak or 
rupture over longer periods of time of weeks and months. 
4.3.5 Surface Functionalization of Protein Microspheres using Layer-By-Layer Adhesion 
Microspheres were centrifugally washed and resuspended in 200 µL of cold PBS 
(pH 7.0). 1mL of cold 1 mg/mL PDDA solution (50 µL PDDA/10 mL PBS) was added to 
the microsphere solution. The solution was mixed and placed on a rotating rotisserie 
shaker for 30 mins in the 4°C refrigerator. The PDDA layer reversed the charge of the 
surface and thereby facilitated the coating of silica nanoparticles. In cases where the silica 
layer was not needed, the RGD was layered directly onto the bare microsphere. 
Microspheres were centrifugally washed at 6000 RPM for 5 mins. The aqueous 
layer was removed and the microspheres were resuspended into 200 µL of cold PBS. One 
milliliter of a 1% silica solution (300 µL of 34% silica/10 mL of PBS) was added to the 
microsphere solution. The solution was lightly mixed and placed on a rotisserie shaker 
for 30 mins in the refrigerator at 4°C. Microspheres layered with silica sank to the bottom 
of the solution during centrifugation. Microspheres still floating in the upper layer likely 
were not successfully layered with PDDA and silica. 
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Next, the microspheres were centrifugally washed at 6000 RPM for 5 mins. The 
aqueous layer was removed, and the microspheres were resuspended into 200 µL cold 
PBS. 1 mL of a 1 mg/mL RGD solution (1 mg RGDKKKKKK peptide/1 mL PBS) was 
added to the microsphere solution. The RGDKKKKKK peptide sequence was 
synthesized by the Protein Sciences Facility at the Roy J. Carver Biotechnology Center at 
the University of Illinois at Urbana-Champaign. The placement of the arginine-glycine-
aspartic acid residues at the amino terminus of the RGDKKKKKK sequence was 
previously reported to be the most optimal linear peptide sequence for targeting the 
microspheres to integrins using the RGD motif [41]. 
4.4 Scanning Electron Microscopy of Protein Microspheres 
Modified protein microspheres were washed with PBS (pH 7.4) 10-15 times to 
purify the sample by removing the excess material. Approximately 15 x 106 microspheres 
were suspended into 850 µL of PBS and 500 µL of the 14% gluteraldehyde solution. The 
solution was vortexed and fixed at room temperature for 2 hrs on the rotating rotisserie 
shaker. The microspheres were washed three times in a 0.1 M Na-Cacodylate buffer    
(pH 7.4) solution for 10 mins each on a shaker. 
The microsphere layer was isolated after being centrifuged at 6000 RPM for a 
period of 5 mins. The microspheres were stained for 2 hrs with 1% osmium tetroxide in a 
0.1 M Na-Cacodylate buffer (pH 7.4) solution on the rotisserie shaker. The microspheres 
were washed three times in a 0.1 M Na-Cacodylate Buffer (pH 7.4) solution for a period 
of 10 mins each on a shaker. 
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The microspheres were gradually dehydrated from 10% ethanol to 25%, 50%, 
75%, 95%, and finally to 100% ethanol (twice) each in 5 mins incubations. The 
microspheres were resuspended in a 1:1 solution of 100% ethanol and 
hexamethyldisilazane (HMDS). Two more washes of the microspheres were performed 
with 100% HMDS. 
The microspheres were resuspended in HMDS and allowed to air dry onto 
nitrocellulose membrane filters (0.22 µm pore size, 13 mm diameter) under the chemical 
fume hood. This method of depositing and drying the microspheres proved to be much 
better than critical point drying of the microspheres. The latter process resulted in a filmy 
layer from the dried alcohol or other solvents on top of the microspheres hindering the 
ability to visualize the finer structures on the microsphere surface. After the HMDS 
evaporated, the membrane filters were secured to SEM chucks with black carbon tape. 
Samples were made conductive for SEM imaging by sputter coating for 90 s to 
achieve a ~20 nm layer of gold/palladium coating using a turbo-pumped sputter coater 
(Denton Vacuum – Model # Desk-1 TSC). The thicker coating permitted the use of 
higher beam intensity and longer imaging times, which enabled higher resolution and 
sharper images. If the coating was too thin, the microspheres easily collapsed under the 
high power beam intensities or under long acquisition time periods of the electron beam. 
The sides of metal chucks were coated with silver paint to provide a continuous 
conducting surface between the gold/palladium coating and the metal chuck. 
Samples were imaged using a scanning electron microscope (SEM) (FEI 
Company – Phillips 30 ESEM-FEG) in the Imaging Technology Group’s Microscopy 
Suite at the Beckman Institute for Advanced Science and Technology at the University of 
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Illinois at Urbana-Champaign. Samples were imaged with an electron beam intensity of 
5.0 kV, a working distance of 3.2 mm, a spot size setting of 2 nm, and magnifications 
ranging from 6,000X to 120,000X. 
SEM images of bare protein microspheres, PDDA-coated microspheres, 
PDDA/Silica-coated microspheres, PDDA/Silica/RGD-coated microspheres, and     
RGD-coated microspheres are shown in Figures 4.3-4.8. The microspheres were 1-5 µm 
in size, which is in agreement with the dynamic light scattering (DLS) results described 
later in this chapter. Differences in the texture of the surface of microspheres can be 
visualized with each added layer. Small (2-5 microspheres) aggregates of protein 
microspheres were found for most of the coatings except for the PDDA-coated 
microspheres, where larger aggregates (50+ microspheres) formed. The layering of 
PDDA and silica provided a very homogeneous and continuous covering of the 
microsphere surface with the respective nanoparticle. Layering of the RGD peptide 
sequence onto the microsphere surface was not as homogeneous or as complete compared 
to the other layers, which could affect the binding affinity of RGD-coated microspheres 
to the integrin receptor. A quantitative estimate of RGD coverage cannot be easily 
determined with SEM since it is difficult to ascertain which particles are due to RGD 
alone, especially when it is layered on top of other layers. In addition, the assumption is 
that the RGD is evenly layered across the entire microsphere surface. For future studies, 
other sequences attached to the RGD should be explored for maximizing the covering of 
the protein microsphere with the RGD increasing the number of exposed RGD ligands 
capable of binding integrin receptors.   
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(a)  
(b)  
(c)  
 
Figure 4.3: Scanning electron microscope images of bare microspheres without any 
additional layers at (a) 5,000X, (b) 25,000X, and (c) 120,000X. The surface of the bovine 
serum albumin protein shell is shown at a higher resolution in the bottom image of the 
sequence.  
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(a)  
(b)  
Figure 4.4: Scanning electron microscope images of microspheres that have been coated 
with PDDA using the layer-by-layer adhesion method at (a) 8,000X and (b) 25,000X. 
This coating reversed the charge on the outer shell of the microsphere in order to allow 
for the layering of silica. Due to this change in the charge, these particular microspheres 
were more likely to aggregate during the SEM processing of these microspheres and 
shown in the resulting SEM images above. Compared to bare microspheres, more texture 
is present on the surface of the microspheres.  
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Figure 4.5: Scanning electron microscope (58593X magnification) images of a 
microsphere that has been coated with a PDDA layer and silica layer using the layer-by-
layer adhesion method. Compared to the PDDA microspheres, the surface of the 
microspheres was completely covered with silica nanoparticles. Microspheres coated 
with silica precipitate to the bottom in solution, making them more suitable for in vitro 
studies where the cells are attached to the bottom of the culture dish.  
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(a)  
(b)  
(c)  
Figure 4.6: Representative scanning electron microscope images of microspheres coated 
with a PDDA layer, then a silica layer, and then a layer of RGD peptide (linear 
RGDKKKKKK) using layer-by-layer adhesion method at 25,000X (a), at 65,000X (b), 
and at 100,000X (c).   
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Figure 4.7: Scanning electron microscope images of microspheres coated with a layer of 
RGD peptide (linear RGDKKKKKK) using the layer-by-layer adhesion method. On the 
smooth surface of bare microspheres, the RGD layer appears textured. Similar to the 
PDDA/Silica/RGD-coated microspheres, the RGD layering does not appear to 
completely cover the microsphere surface.  
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(a)  (b)  
(c)  (d)  
 
Figure 4.8: Summary of representative SEM images of protein microspheres [(a), (b), (d) 
at 25,000X; (c) at 58,593X magnifications] through each layering process via layer-by-
layer electrostatic adhesion process. Bare microspheres before any layering (a); RGD 
layered directly onto the bare microspheres (b); bare microspheres first layered with 
PDDA and then with silica (c); bare microspheres first layered with a layer of PDDA 
followed by silica and followed by RGD (d).  
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4.5 Transmission Electron Microscopy of Protein Microspheres 
The processing of microspheres for transmission electron microscopy (TEM) 
followed the same procedure as the SEM processing for the fixation, washing, staining, 
washing, and dehydration steps. Compared to SEM processing, the microspheres were 
left suspended in 100% Ethanol as the final step for TEM processing. In SEM processing, 
the microspheres were resuspended in HDMS as the final step. 
The fixed microspheres were washed and infiltrated with an epoxy resin. They 
were first suspended in a 1:1 mixture of ethanol and acetonitrile for 10 mins. The 
microspheres were resuspended into a 100% solution of acetonitrile for an additional     
10 mins. The epoxy resin was a solution of Embed 812 Mixture (Electron Microscopy 
Sciences) with DMP-30, an epoxy accelerator. The microspheres were suspended into a 
1:1 mixture of acetonitrile and the Embed 812 with DMP-30 epoxy resin solution for    
10 mins. They were then suspended into a 100% epoxy resin solution and allowed to 
fully infiltrate overnight at room temperature. The microspheres were embedded into the 
epoxy resin and cured in a vacuum-sealed oven at 60°C for 3 days. The cured samples 
were cooled to room temperature and sectioned using a diamond knife in 100 nm slices 
on an ultramicrotome (Leica Ultracut UCT). The sections were placed on copper mesh 
grids (Electron Microscopy Sciences, 200 Mesh Copper Gilder Grids, G200-Cu) and 
imaged with a transmission electron microscope (Philips CM200) at a voltage of 120 kV. 
Representative TEM images of each layer are presented in Figure 4.9. Due to 
differences in the staining penetration of the osmium tetroxide of the layered particles, 
distinct layers could not always be observed. Distinct structural differences and particle 
distribution can be seen with each added layer along with the encapsulated iron oxide.  
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(a) Bare Microspheres 
 
(b) PDDA-coated 
 
(c) PDDA – Silica-coated 
 
(d) PDDA – Silica – RGD-coated 
Figure 4.9: TEM images of protein microspheres through each layering process via layer-
by-layer electrostatic adhesion process. TEM images of (a) bare microspheres before any 
layering; (b) bare microspheres layered with PDDA; (c) bare microspheres layered with 
PDDA and silica; (d) bare microspheres layered with PDDA, Silica, and RGD. Iron oxide 
particles can be seen in the oil core of the microspheres (a, b).  
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4.6 Size Distribution of Protein Microspheres 
The size distribution of protein microspheres using this synthesis method was 
previously reported by Prof. Suslick’s research group as 1-3 µm [38, 39]. The size 
distribution of protein microspheres was found to be largely dependent on the surface 
tension between the oil phase and the BSA protein phase during the emulsification 
process of the sonochemical synthesis of microspheres [38, 39]. Other factors such as the 
ultrasonic power intensity and acoustic frequency affected the yield of microspheres but 
not their size. The size distribution is an important parameter to control because it 
influences the in vivo circulation pattern and lifetime of the protein microspheres.  
While determining the loading capacity of protein microspheres to encapsulate 
various magnetic and fluorescent nanoparticles of interest, I studied the effects of 
increasing the concentrations of encapsulated Nile Red dye, DiR dye, and iron oxide on 
the microsphere size distribution. In order to maximize the contrast under magnetic 
imaging modalities (MM-OCT and MRI) and fluorescence imaging modalities, the 
microspheres should encapsulate the maximum amount of dye or iron oxide into the inner 
core. The size distribution of these microspheres was measured to determine the effects 
of increased nanoparticles in the inner core on the final microsphere size distribution. 
A DLS instrument (Accusizer FX Particle Sizer) located in the Microscopy Suite 
of the Imaging Technology Group of the Beckman Institute for Advanced Science and 
Technology at the University of Illinois at Urbana-Champaign measured the size 
distribution and quantified the concentration of microspheres. The instrument uses a flow 
system to pass the particles through the detection channel. This method provided more 
reproducible measurements of the size distribution of the particles and quantifying the 
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particle concentration compared to the cuvette-based DLS instrument due to the 
properties of the synthesized microspheres. Microspheres will precipitate over time to the 
bottom of the vial during the DLS imaging studies. When the microspheres are initially 
suspended in hydrophilic solutions, they easily separated into a top layer, moving out of 
the imaging volume of the cuvette cell over the course of the DLS imaging session over 
time. This effect contributed to large variations in the measured size distribution using the 
cuvette-based DLS instrument compared to the flow-based DLS instrument. It was also 
found that the solvent used to re-suspend the microspheres could lead to the aggregation 
of the microspheres such as the case when comparing between H2O and PBS (Figure 
4.10). The presence of a second peak was attributed to the aggregation of microspheres 
that occurred when the microspheres were resuspended in water as opposed to PBS. This 
peak decreased in size but did not completely disappear when the sample was sonicated 
for a period of several hours just prior to the DLS imaging session. 
The results of the DLS measurements from the iron oxide-filed microspheres 
(Figure 4.11), the Nile Red-filed microspheres (Figure 4.12), and the DiR-filed 
microspheres (Figure 4.13) showed little changes in the size distribution of the 
microspheres. The size distributions reported here are similar to those previously 
synthesized and reported by Prof. Suslick’s research group using similar synthesis 
protocol [38, 39]. Using a Coulter counter, the size distribution of microspheres was 
primarily between 1-3 µm with the right tail of the distribution ending DLS light 
scattering and the Coulter counter are acceptable methods for measuring the size 
distribution of microspheres.  
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(a)  
(b)  
Figure 4.10: DLS size measurements of the same four batches of iron oxide-filled 
microspheres that were re-suspended into water (H2O) (a) or into PBS (b). The solvent 
used to suspend the microspheres contributes to the aggregation of microspheres as 
observed by the larger size distribution and extra peak between 3-5 µm. The second 
largest peak at ~3.4 µm was largely attributed to the aggregation of 2-3 microspheres. 
Disrupting the aggregates via sonication can also reduce this peak   
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Iron Oxide (Fe2O3) Concentration 
of Oil Stock Solution 
 Iron Oxide (Fe2O3) Concentration 
of Oil Stock Solution 
Fe-00 0.0 mg/mL Fe-07 15 mg/mL 
Fe-01 0.5 mg/mL Fe-08 20 mg/mL 
Fe-02 0.2 mg/mL Fe-09 40 mg/mL 
Fe-03 1.0 mg/mL Fe-10 60 mg/mL 
Fe-04 2.0 mg/mL Fe-11 80 mg/mL 
Fe-05 5.0 mg/mL Fe-12 100 mg/mL 
Fe-06 10 mg/mL   
Figure 4.11: Size distribution of protein microspheres with increasing concentration of 
encapsulated iron oxide nanoparticles. As the concentration of iron oxide is increased, 
there is very little change in the size distribution. The main peak of the protein 
microspheres is located at ~1.3 µm.  
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Nile Red Dye Concentration 
of Oil Stock Solution 
 Nile Red Dye Concentration 
of Oil Stock Solution 
NR-00 0.0 mg/mL NR-06 0.6 mg/mL 
NR-01 0.1 mg/mL NR-07 0.7 mg/mL 
NR-02 0.2 mg/mL NR-08 0.8 mg/mL 
NR-03 0.3 mg/mL NR-09 0.9 mg/mL 
NR-04 0.4 mg/mL NR-10 1.0 mg/mL 
NR-05 0.5 mg/mL   
 
Figure 4.12: Size distribution of protein microspheres with increasing concentration of 
encapsulated Nile Red dye molecules. As the concentration of Nile Red is increased, 
there was very little change in the size distribution.  
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DiR Dye Concentration 
of Oil Stock Solution 
 DiR Dye Concentration 
of Oil Stock Solution 
DiR-00 0.0 mg/mL DiR-03 3.0 mg/mL 
DiR-01 1.0 mg/mL DiR-04 4.0 mg/mL 
DiR-02 2.0 mg/mL DiR-05 5.0 mg/mL 
 
 
Figure 4.13: Size distribution of protein microspheres with increasing concentration of 
encapsulated DiR dye molecules. As the concentration of DiR is increased, there was 
very little change in the size distribution.  
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4.7 Conclusions 
Protein microspheres were successfully synthesized using a modified protocol 
from Prof. Suslick’s laboratory. They were successfully encapsulated with commercially 
available iron oxide nanoparticles, Nile Red dye, and DiR dye for use in MM-OCT, MRI, 
wide field fluorescence imaging system, and fluorescence microscopy. Protein 
microspheres layered with PDDA, silica, and RGD peptide were visualized using 
scanning electron microscopy and transmission electron microscopy. The size 
distribution and concentration of the protein microspheres was characterized using a 
flow-based DLS instrument. The type and concentration of encapsulated particles did not 
have any effect on the overall size distribution or synthesis yield of the protein 
microspheres. The DLS measurements indicated that the measurement variability within 
the sample and across samples of the same microsphere type to be minimal. DLS was 
identified as a suitable method to rapidly quantify the concentration and characterize the 
size distribution of microspheres. The size distribution reported from the DLS 
measurements indicated that the majority of the protein microspheres were 1-2 µm in size 
with a smaller distribution in the 2-5 µm, which is consistent with the sizes observed 
under SEM reported in Figures 4.3-4.8. The size distribution was also consistent with 
previously reported measurements via the Coulter counter. This characterization was 
necessary to ensure minimal intersample variability when scaling up the synthesis of 
microspheres for in vivo or ex vivo animal experiments.  
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CHAPTER 5 
PROTEIN MICROSPHERES AS CONTRAST AGENTS 
5.1 Introduction 
Modified protein microspheres have great potential as novel multi-modal contrast 
agents. This chapter will focus on the development and evaluation of protein microspheres as 
magnetic contrast agents for MM-OCT [1] and MRI. The encapsulation capacity of iron oxide 
into the microspheres was increased to maximize the magnetic contrast. The fluorescence 
properties of these microspheres were evaluated with wide-field fluorescence imaging and 
fluorescence microscopy. These imaging modalities will be evaluated for their potential to 
detect and quantify the concentration of iron oxide-filled microspheres and fluorescent dye 
filled microspheres in samples. Being able to quantify the concentration of microspheres in a 
sample would provide information about the binding specificity and relative bio-distribution 
of the microspheres when examined in an in vivo animal experiment. Lastly, the effects of 
combining both the iron oxide and the dyes into a single multi-modal protein microsphere will 
be explored. 
5.1.1 Previous Uses of Protein Microspheres as Imaging Agents 
Protein microspheres have been previously reported for use as imaging agents in a 
number of different biomedical applications. Iron oxide colloids were first embedded into the 
shell of protein microspheres by Kolbeck [2] and encapsulated into the oil core of protein 
microspheres by Toublan [3]. Iron oxide protein microspheres were first developed as contrast 
agents for histopathological analysis [2] as the iron oxide could be stained with Prussian Blue. 
Gadolinium and perfluoronane filled protein microspheres were explored as magnetic contrast 
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agents for MRI applications [2]. Air-filled and oil-filled microspheres have been widely 
explored for contrast and drug delivery applications in ultrasound [2, 4]. Fluorescent 
microspheres were developed for fluorescence microscopy and spectroscopic OCT [2, 3, 5]. 
Protein microspheres, modified with carbon, gold, or melanin, have also been studied as 
scattering contrast agents for OCT [3, 6]. The diversity of microsphere types developed over 
the years for different imaging modalities reinforces the high level of customization and 
flexibility available with protein microspheres. Most of the studies to date using protein 
microspheres as contrast agents have focused on single imaging applications. The work 
presented in this thesis reveals the first in-depth efforts for the development and optimization 
of protein microspheres as multi-modal contrast agents that can bridge imaging modalities 
that respectively image on different scale sizes. 
5.2 Protein Microspheres as Magnetic Contrast Agents 
One main application for the modified microspheres described in this thesis would be 
to serve as magnetic contrast agents in MM-OCT [1]. As previously described, MM-OCT 
provides additional functional contrast to structural OCT images by modulating a magnetic 
field off and on during OCT imaging. The magnetomotive contrast is dependent on the 
physical displacement of scatterers caused by the movement of magnetic particles when the 
field is turned on. As part of the multi-modal design of this microsphere, magnetic 
nanoparticles encapsulated by the microsphere should also be detectable under MRI, a wide-
field biomedical imaging modality. 
In the following studies, the protein microspheres were synthesized using an oil stock 
solution with a concentration of 50 mg of iron oxide/mL of vegetable oil. The protein 
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microspheres were washed and purified as previously described in Chapter 4 and 
characterized using a flow-based DLS instrument. Different samples (1% low melting agarose 
gel) were made with different concentrations of microspheres. The final gel volume at the 
same final 1% concentration of agarose gel should correlate to similar overall stiffness across 
the different samples (Table 5.1). The assumption made was that the amount of microspheres 
in the final gel samples would not significantly contribute to the overall gel stiffness. Since 
the MM-OCT signal is dependent on the physical displacement of scatterers by magnetic 
particles, the stiffness of the sample plays a significant role in the displacement magnitude of 
the scatterers. The sample stiffness was inversely correlated with the distance the magnetic 
particles were able to displace the surrounding scatterers. 
 
Table 5.1: Increasing concentrations of microspheres suspended in 1% low melting agarose 
gel. The resulting approximate microsphere concentrations ranged from ~5.3 x 106 to 2.6 x 
107 microspheres/mL of agarose gel. 
Name Microsphere Stock Volume 
PBS 
Volume 
1% Low Melting 
Agarose Volume 
Total 
Volume 
Microsphere Conc. 
(# of Microspheres/mL 
of solution) 
Sample 1 000 uL 200 uL 7.0 mL 7.2 mL 0/mL 
Sample 2 040 uL 160 uL 7.0 mL 7.2 mL 5.3 x 106/mL 
Sample 3 080 uL 120 uL 7.0 mL 7.2 mL 1.1 x 107/mL 
Sample 4 120 uL 080 uL 7.0 mL 7.2 mL 1.6 x 107/mL 
Sample 5 160 uL 040 uL 7.0 mL 7.2 mL 2.1 x 107/mL 
Sample 6 200 uL 000 uL 7.0 mL 7.2 mL 2.6 x 107/mL 
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5.2.1 Iron Oxide-filled Microspheres under MM-OCT 
The MM-OCT images (Figure 5.1) demonstrate that these microspheres can provide 
MM-OCT contrast at concentrations between 5.3 x 106 and 1.6 x 107 microspheres/mL in the 
1% low melting temperature agarose gel. The MM-OCT signal intensity pixel values were 
averaged over the entire image and plotted as a function of the microsphere concentration in 
Figure 5.2. This plot shows that MM-OCT can quantitatively measure the microsphere 
concentration derived from the average magnetomotive intensity signals for samples at 
concentrations less than 1.1 x 107 microspheres/mL of gel (with iron oxide concentration of 
50 mg/mL in the inner core). At concentrations greater than 1.1 x 107 microspheres/mL, the 
MM-OCT signal reached a plateau around an MM-OCT signal of 4.5-5.5 dB. The plateau 
occurs when the amplitude of the displacement of the scatterer, as the magnetic field is 
modulated, is large enough that the optical phase changes by more than π [7]. When this 
occurs, it is not possible to properly unwrap the optical phase. 
MM-OCT can also be used to quantify the number of microspheres with known 
concentration of encapsulated iron oxide. Oil stock solutions were prepared with increasing 
iron oxide concentrations from 0 to 100 mg/mL as described in Table 5.2. The microspheres 
were synthesized using these initial stock solutions and embedded into 1% low melting 
temperature agarose gels at concentrations of 1.0 x 107 microspheres/mL in 35 mm x 10 mm 
petri dishes. The average MM-OCT intensity signals are plotted as a function of the 
concentration of iron oxide encapsulated in the protein microspheres in Figure 5.4.   
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Concentration = 0 microspheres/mL 
 
Concentration = ~5.3 x 106 microspheres/mL 
 
Concentration = ~1.1 x 107 microspheres/mL 
 
Concentration = ~1.6 x 107 microspheres/mL 
 
Concentration = ~2.1 x 107 microspheres/mL 
 
Concentration = ~2.6 x 107 microspheres/mL 
Figure 5.1: MM-OCT images of 1% agarose gels with increasing microsphere concentration 
  
200 µm 
200 µm 
200 µm 
200 µm 
200 µm 
200 µm 
  127 
 
Figure 5.2: MM-OCT signal as a function of increasing microsphere concentration with a 
constant iron oxide concentration per microsphere. Average MM-OCT signal was calculated 
by averaging the MM-OCT signal across all the pixels in the image.  
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According to the MM-OCT images (Figure 5.3) and plot of MM-OCT signal intensity 
as a function of iron oxide/microsphere synthesis concentration (Figure 5.4), the MM-OCT 
signal increased linearly with increasing encapsulated iron oxide concentrations up until about 
40 mg of iron oxide/mL of oil of the stock solution at the time of synthesis. At higher 
concentrations, the average magnetomotive signal began to plateau suggestive of a maximum 
amount of iron oxide that could be encapsulated into these particular protein microspheres. 
This trend was also observed experimentally during the protein microsphere synthesis. As the 
iron oxide concentration of the oil stock solutions was increased, increasing amounts of 
excess iron oxide pelleted to the bottom during centrifugal washing of the protein 
microspheres. This resulted in an increasing number of washes needed to achieve a clear 
aqueous layer. This trend was also observed with MRI data used to quantify the iron oxide 
encapsulated inside the microsphere presented later in this chapter. The last data point shows 
an increase above the initial plateau, which may be unreliable due to the phase wrapping 
issues previously described. When looking at the corresponding MM-OCT image in Figure 
5.3 (Fe-11), the MM-OCT image is saturated in various areas, individual scatterers cannot be 
easily distinguished from one another compared to the other images in Figure 5.3. 
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Table 5.2: Microspheres encapsulated with increasing concentrations of iron oxide in 1% low 
melting agarose gels. 
 
Label Iron Oxide Conc. Microsphere Volume PBS Volume Agarose Gel Volume Total Volume 
Fe-00 0.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-01 0.5 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-02 1.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-03 2.0 mg/mL 75µL 125 µL 7.0 mL 7.2 mL 
Fe-04 5.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-05 10.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-06 15.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-07 20.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-08 40.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-09 60.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-10 80.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
Fe-11 100.0 mg/mL 75 µL 125 µL 7.0 mL 7.2 mL 
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Fe-00 = 0.0 mg iron oxide/mL Oil 
 
Fe-05 = 10.0 mg iron oxide/mL Oil 
 
Fe-01 = 0.5 mg iron oxide/mL Oil  
 
Fe-06 = 15.0 mg iron oxide/mL Oil  
 
Fe-02 = 1.0 mg iron oxide/mL Oil  
 
Fe-08 = 40.0 mg iron oxide/mL Oil  
 
Fe-03 = 2.0 mg iron oxide/mL Oil  
 
Fe-09 = 60.0 mg iron oxide/mL Oil  
 
Fe-04 = 5.0 mg iron oxide/mL Oil  
 
Fe-10 = 80.0 mg iron oxide/mL Oil  
 
Fe-11 = 100.0 mg iron oxide/mL Oil  
Figure 5.3: Representative MM-OCT images of agarose gels of protein microspheres with 
increasing concentration of encapsulated iron oxide. The microspheres were suspended into 
1% agarose gels at a concentration of ~1.0 x 107 microspheres/mL.  
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Sample 
Name 
Concentration of 
Iron Oxide 
in Oil Stock Solution 
Sample 
Name 
Concentration of 
Iron Oxide 
in Oil Stock Solution 
Fe-00 0.0 mg/mL Fe-06 15.0 mg/mL 
Fe-01 0.5 mg/mL Fe-07 20.0 mg/mL 
Fe-02 1.0 mg/mL Fe-08 40.0 mg/mL 
Fe-03 2.0 mg/mL Fe-09 60.0 mg/mL 
Fe-04 5.0 mg/mL Fe-10 80.0 mg/mL 
Fe-05 10.0 mg/mL Fe-11 100.0 mg/mL 
 
Figure 5.4: MM-OCT signal as a function of increasing inner core iron oxide concentration 
inside the microsphere with a constant concentration of microspheres per volume of agarose 
gel. Microspheres were embedded into a 1% agarose gel at a concentration of 106 / mL of gel.  
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5.2.2 Quantification of Encapsulated Iron Oxide using MRI 
The saturation of the MM-OCT signal observed in Figure 5.4 could be due to a couple 
of reasons including the saturation limits of the imaging system or reaching the maximum 
encapsulation concentration of iron oxide in the protein microsphere. To determine the cause 
of the saturation, it was necessary to identify a method to quantify the amount of iron oxide 
encapsulated in the microsphere. Several methods were explored to quantify the amount of 
iron oxide to determine if the maximum encapsulation capacity of iron oxide had been 
reached. Methods for accurately measuring the amount of iron oxide concentration include 
magnetic relaxometry and Prussian blue staining [8, 9]. Prussian blue staining can penetrate 
the protein shell and stain the encapsulated iron oxide when allowed to stain for a period of at 
least 25-30 minutes. To quantify the iron concentration using Prussian blue staining, 
absorption spectra of the stained microspheres was measured using a Beckman DU-640 
spectrophotometer over the range of 190-1100 nm. The main absorption peak for Prussian 
blue is at 650 nm. Although the Prussian blue clearly stained the iron oxide particles inside 
the microspheres on visual inspection when compared to microspheres without iron oxide, the 
broad and strong absorption of the microsphere interfered with the detection of the Prussian 
blue absorption peak. 
MRI was another potential method for quantifying the iron oxide concentration in 
microspheres. Superparamagnetic iron oxide (SPIO) nanoparticles have been extensively 
studied as MRI contrast agents both in vitro and in vivo for cancer applications [9-31]. The 
14.1 Tesla Varian system with a bore magnet 89 mm in size and a 600 MHz Varian Unity / 
Inova NMR spectrometer from the Biomedical Imaging Center of the Beckman Institute for 
Advanced Science and Technology at the University of Illinois at Urbana-Champaign was 
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used. From the MRI studies presented in Figures 5.5-5.10, the iron oxide nanoparticles in oil 
or the iron oxide-filled protein microspheres were suspended in 1% low melting agarose gels. 
The gels were allowed to solidify in capillary tubes. To reduce the formation of air bubbles 
and the potential settling of microspheres that would contribute to sample inhomogeneities, 
the capillary tubes were vortexed and placed into a water bath at room temperature to 
facilitate a rapid and uniform solidification process. The MRI measurements were taken at 
four different echo times of 3.3 ms, 5.0 ms, 7.0 ms, and 9.0 ms. Nineteen MRI slices were 
taken throughout the full volume of the gel in the capillary tubes. 
A standard curve was created using the MRI measurements from agarose gels with 
increasing concentrations of iron oxide nanoparticles between 10-25 µg of iron oxide/mL of 
agarose gel. The mean MRI signals as a function of the echo times are plotted in Figure 5.5. 
From this data, the relaxation times (T2*) were extracted using a Matlab script code and the 
relative volume distribution plotted as a function of the T2* values. The relaxation rates (R2*) 
were calculated from the T2* values and plotted against the concentration of iron oxide (mM) 
demonstrating a linear correlation as shown in Figure 5.6. The relaxivity per iron oxide 
particle was determined by fitting a linear regression line to the plot in Figure 5.6. The 
relaxivity was found to be 621.0 mM-1s-1 per iron oxide (Fe2O3) particle or 310.5 mM-1s-1 per 
iron particle using a 14.1 T field, which is on the same order of magnitude to previously 
published reports of 500-550 mM-1s-1 for Fe2O3 using a 4.7 T field [11], 134 mM-1s-1 for 
Fe2O3 using a 1.5 T field [13], and 61.16-505 mM-1s-1 per Fe of iron oxide particles [12]. The 
variability in relaxivity depends on several factors including the core size of the iron oxide 
and the ligands that are complexed with the iron oxide [11-13, 22, 23].  
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Figure 5.5: MRI measurements of agarose gels with increasing concentrations of iron oxide. 
On the left side is a representative MRI slice from a volume of 19 images taken. The graph on 
the right plots the mean normalized MRI signal from the 19 images against the echo time.  
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Figure 5.6: Plot of relaxation rate [R2* or 1/T2* (s-1)] as a function of the non-encapsulated 
iron oxide concentration of the gel phantoms. The relaxivity, r2, calculated from the slope of 
the plot was determined to be 621.0 mM-1s-1. 
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Figure 5.7: MRI measurements of agarose gels with increasing concentration of microspheres 
with constant inner iron oxide concentration (oil stock solution iron oxide concentration = 
15.0 mg/mL). On the left side is a representative MRI slice from a volume of 19 images 
taken. The graph on the right plots the mean normalized MRI signal from the 19 images 
against the echo time.  
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Figure 5.8: Plot of relaxation rate [R2* or 1/T2* (s-1)] as a function of the microsphere 
concentration (# / mL). The iron oxide concentration of the oil stock solution used for the 
microsphere synthesis was constant at 15.0 mg/mL. 
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A similar experiment using increasing concentrations of iron oxide-filled microspheres 
was performed to determine the upper limit for quantifying the microsphere concentration 
using the MRI system. Agarose gels with increasing concentrations of microspheres ranging 
from 6 x 105 to 2.6 x 106 microspheres/mL were imaged. The inner core iron oxide 
concentration per microsphere was kept constant with an oil stock iron oxide concentration of 
15.0 mg/mL. The MRI data is presented in Figure 5.7. The relaxation rates (R2*) were 
calculated from the T2* values and plotted against the microsphere concentration 
demonstrating a linear correlation (Figure 5.8). 
A subset of the microspheres previously prepared for the MM-OCT iron quantification 
experiment presented in Table 5.2 and Figure 5.3 was used for the MRI iron quantification 
experiment in Table 5.3. 
 
Table 5.3: Relative Iron Oxide Concentration of Iron Oxide-filled Protein Microspheres used 
for MRI Experiments. 
 Concentration of Iron Oxide at Synthesis Time 
Fe-00 0.0 mg/mL 
Fe-02 1.0 mg/mL 
Fe-04 5.0 mg/mL 
Fe-06 15.0 mg/mL 
Fe-07 20.0 mg/mL 
Fe-08 40.0 mg/mL 
Fe-09 60.0 mg/mL 
Fe-10 80.0 mg/mL 
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The iron oxide-filled microspheres were suspended in 1% low melting agarose gels at 
a concentration of ~2.0 x 106 microspheres/mL of gel and allowed to solidify inside the 
capillary tubes as previously described. The T2* values were extracted from the average MRI 
values over the volume of 19 MRI slices at the four echo times: 3.3 ms, 5.0 ms, 7.0 ms, and 
9.0 ms. 
Using the iron oxide concentration standard curve in Figure 5.6, the iron oxide 
concentrations were calculated from the T2* values. Using the concentration of microspheres 
measured from the DLS instrument, the iron oxide concentration per microsphere was 
calculated and plotted in Figure 5.11. A linear trend was observed at concentrations lower 
than 20 mg/mL of iron oxide in the oil stock solution (Figure 5.12). At oil stock 
concentrations of iron oxide greater than 20 mg/mL, the T2* values became constant (Figure 
5.11). This trend indicated that the maximum encapsulated iron oxide/microsphere 
concentration had been reached. These findings agree with the MM-OCT results in Figure 5.3 
and Figure 5.4, which found the maximum average magnetomotive OCT signal/microsphere 
reaching a plateau for microspheres made with iron oxide oil stock concentrations greater than 
20-40 mg/mL. The MRI and MM-OCT both confirm the presence of an upper limit for 
encapsulating iron oxide nanoparticles into the protein microspheres. Based on these results, 
the average maximum effective amount of iron oxide encapsulated into a single microsphere 
was determined to be approximately ~14 ng. These calculations are made on the assumption 
that the encapsulation of iron oxide inside the microspheres does not change the relaxivity of 
iron oxide since the iron oxide was suspended in the oil in both samples. The 
microenvironment surrounding the iron oxide should be fairly similar between the non-
encapsulated and encapsulated iron oxide.  
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Figure 5.9: MRI measurements of agarose gels with microspheres of increasing inner core 
iron oxide concentration. On the left side is a representative MRI slice from a volume of 19 
images taken. The graph on the right plots the mean normalized MRI signal against the echo 
time.  
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Figure 5.10: MRI measurements of agarose gels with microspheres of increasing inner core 
iron oxide concentration. On the left is a representative MRI slice from a volume of 19 images 
taken. The graph on the right plots the mean normalized MRI signal against the echo time. 
  
Agarose  
0.0 mg/mL 
80.0 mg/mL 
40.0 mg/mL 
60.0 mg/mL 
Agarose Gel 
20.0 mg/mL 
40.0 mg/mL 
80.0 mg/mL 
60.0 mg/mL 
  142 
 
 
T2* 
iron oxide concentration during 
synthesis - mg/mL ng iron oxide / # of Microspheres 
Agarose N/A 0 0 
Fe-00 N/A 0 0 
Fe-02 11.7 1 4.2 
Fe-04 12.6 5 3.2 
Fe-06 4.5 15 12.5 
Fe-07 3.4 20 13.6 
Fe-08 3 40 14.0 
Fe-09 2.9 60 14.1 
Fe-10 2.8 80 14.2 
Figure 5.11: The iron oxide / microsphere concentration calculated from the measured T2* 
value and plotted against the initial concentration of iron oxide in the oil stock solution used 
to synthesize the protein microspheres.  
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Figure 5.12: Zoomed in graph of Figure 5.11 demonstrating the linear relationship of iron 
oxide / microsphere concentration as a function of the initial concentration of iron oxide in the 
oil stock solution used to synthesize the protein microspheres.  
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5.3 Protein Microspheres as Fluorescent Contrast Agents 
Fluorescent dyes such as FITC, Bodipy, Nile Red, and Heptamethylcyanine NIR dye 
have previously been encapsulated into protein microspheres [1-3]. The use of NIR dyes is 
most advantageous in the field of biomedical optical imaging due to the deeper penetration 
depth possible with NIR light. In this region of the spectrum, the fluorescence peak of the 
encapsulated dye should have minimal overlap with the strong tissue autofluorescence found 
in the visible region of the spectrum. The NIR dye previously encapsulated by Toublan was 
reported to be unstable, resulting in a loss of the fluorescence properties within 24 hours of 
synthesis [3]. In addition, the peak absorption for this particular NIR dye is at 800 nm, which 
is above the current maximum excitation wavelength (760 nm) of the wide-field fluorescence 
imaging system (CRi Maestro) in our laboratory. This section focuses on the encapsulation of 
DiR iodide [1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide], a NIR 
fluorescent dye, optimizing the protein microspheres for the wide-field fluorescence imaging 
system, and studying the effects of encapsulating both magnetic and fluorescent agents into a 
single microsphere on its fluorescence properties. 
Nile Red [5H-benzo-phenoxa-5-one-9-diethylamine] filled microspheres have 
previously been synthesized and characterized by Prof. Suslick’s research group [3, 5]. The 
Nile Red-filled microspheres were previously reported to have an emission peak at 
approximately 580 nm when excited between 450 nm and 550 nm [3, 5]. The encapsulation 
efficiency of Nile Red into the microspheres was reported to be at 68% for Nile Red-filled 
BSA microspheres [5]. The Nile Red-filled microspheres can be used in both the wide-field 
fluorescence imaging system for small animal in vivo imaging and on a standard fluorescence 
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or confocal microscope for histopathological analysis. The latter application may be useful for 
confirming the localization of microspheres or their contents in tissue. 
DiR is part of a group of lipophilic dyes commonly used to stain lipids such as 
membranes for cellular applications. DiR has a reported excitation maximum at 750 nm and a 
maximum emission at 780 nm. DiR was initially suspended in hexane and dissolved into the 
oil stock solution. The hexane was evaporated in a protocol similar to the Nile Red and iron 
oxide oil suspensions. Although the dye appeared to be well dissolved in the oil and assumed 
to be encapsulated into the microspheres, the fluorescence properties of the DiR were vastly 
diminished during this process. The 80°C water bath used to evaporate the hexane was too 
high, causing a large loss in the fluorescence properties of DiR and a shift in the fluorescence 
excitation and emission. Other solvents were explored to make the DiR more miscible in oil 
while conserving the absorption and fluorescence properties of DiR. Methanol, ethanol, 
dichloromethane [32], and hexane were used to dissolve the DiR into the oil suspension. The 
solvents were evaporated by placing them in a water bath at temperatures listed in Table 5.4 
and by bubbling nitrogen gas through the oil solution during the evaporation. 
 
Table 5.4: Solvents Used to Dissolve DiR into Vegetable Oil. 
Solvent Boiling Point Temperature Used for Evaporation 
Ethanol 78°C 55°C 
Methanol 65°C 55°C 
Dichloromethane 40°C 55°C 
Hexane 69°C 55°C 
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Microspheres were synthesized from each of these resulting oil stock solutions and 
embedded into 1% agarose gel phantoms at equal microsphere concentrations. The gel 
samples were imaged using the wide-field imaging system with an excitation window 
between 670 nm and 710 nm, and an emission detection window greater than 750 nm. The 
results in Figure 5.13 indicated that the use of ethanol, nitrogen bubbling, and the lower water 
bath temperature proved to be the most successful in preserving the fluorescence properties of 
the dye during the microsphere synthesis process. 
 
 
Figure 5.13: Relative fluorescence intensity of DiR encapsulated microspheres prepared using 
different solvents to dissolve the DiR into the oil.  
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Given the sensitivity of DiR to elevated temperatures and light exposure, additional 
studies examined the stability of the absorption and fluorescence properties of the DiR 
through each major step of the microsphere synthesis. The absorption spectra of DiR in oil, 
and of the synthesized DiR-filled microspheres were measured on a UV-VIS 
spectrophotometer (Synergy H1 Multi-Mode Reader). The fluorescence spectra were acquired 
on the wide-field fluorescence imaging system (CRi Maestro) using an excitation light source 
at 670-710 nm The main regions of interest for DiR are 600-900 nm for the excitation peak 
and 700-950 nm for the emission peak. The results, presented in Figure 5.14, show a slight 
red shift in both the absorption and emission peaks of DiR once dissolved into vegetable oil 
with little to no significant changes to the spectral shape of the DiR absorption and emission 
peaks.	  
Similarly, the absorption and fluorescence properties of the Nile Red dye was also 
measured through each step of the Nile Red-filled protein microsphere synthesis. The 
absorption spectra of Nile Red in oil, and of the synthesized Nile Red-filled protein 
microspheres were measured on a UV-VIS spectrophotometer (Synergy H1 Multi-Mode 
Reader). The fluorescence spectra were measured on the wide-field fluorescence imaging 
system (CRi Maestro) using an excitation light source at 503-555 nm. Compared to the DiR, 
there was a blue shift in both the absorption and fluorescence spectra for the Nile Red once it 
was dissolved into the oil and encapsulated inside the microsphere (Figure 5.15). Based on 
these spectra, the encapsulation process had minimal effect on the absorption and 
fluorescence spectral shape and location. 
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(a)  
(b)  
 
 Peak Excitation Wavelength Peak Emission Wavelength 
DiR 750 nm 779 nm 
DiR in Oil 770 nm 790 nm 
DiR in Microspheres 760 nm 790 nm 
Fluorescence Imaging System 670-710 nm > 750 nm 
Figure 5.14: Absorption (a) and fluorescence (b) properties of DiR through each major step of 
microsphere synthesis. *Absorption and fluorescence data from manufacturer (Life 
Technologies). **Fluorescence data was acquired using excitation at 670-710 nm.  
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(a)  
(b)  
 
 Excitation Wavelength Emission Wavelength 
Nile Red* 553 nm 637 nm 
Nile Red in Oil** 525 nm 610 nm 
Nile Red in Microspheres** 528 nm 610 nm 
Fluorescence Imaging System 503-555 nm > 580 nm 
Figure 5.15: Absorption (a) and fluorescence (b) properties of Nile Red through each major 
step of the microsphere synthesis. *Absorption and fluorescence data from manufacturer (Life 
Technologies). **Fluorescence data was acquired using excitation at 503-555 nm.   
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5.3.1 Protein Microspheres under the Wide-field Fluorescence Imaging System 
The wide-field fluorescence imaging system was used to detect and to quantify the 
microspheres in gels using the measured fluorescence signal. The optimum concentration of 
microsphere for detection by the fluorescence imaging system was assessed. In addition, since 
there was not necessarily a high overlap between the bandpass filter windows provided by the 
instrument and the excitation peaks of the fluorophores (DiR and Nile Red), it was necessary 
to ensure that there was adequate overlap to excite and detect the fluorophores. 
Two batches of microspheres were synthesized to examine two different spectral 
regions. The DiR-filled microspheres were synthesized using an oil stock solution with a 
concentration of 50 mg/mL of iron oxide and 10 mg/mL of DiR. The average fluorescence 
intensity per pixel in the region of interest increased linearly with the concentration of 
microspheres. The Nile Red-filled microspheres were made using an oil stock solution with a 
concentration of 50 mg/mL of iron oxide and 1 mg/mL of Nile Red dye. Similar to the DiR-
filled microspheres, a linear trend was observed with increasing microsphere concentrations 
(Figure 5.17 and Figure 5.18). At microsphere concentrations greater than 3.7 x 106/mL, the 
fluorescence signal saturated the detection system. 
Each fluorescent dye has its advantages and disadvantages. A disadvantage of Nile 
Red-filled microspheres is the strong overlap with tissue autofluorescence within the visible 
range, making it potentially difficult to spectrally resolve during in vivo targeting experiments 
in rats. The advantage of using the spectral range of DiR is the deeper tissue penetration with 
NIR light. There is also less spectral overlap between the emission spectrum of DiR and tissue 
autofluorescence. In contrast, the primary advantage of Nile Red-filled microspheres is that 
they have higher fluorescence intensities compared to DiR-filled microspheres due to both the 
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higher degree of overlap between the absorption peak and the imaging system’s bandpass 
filter window and the higher quantum efficiency of the Nile Red dye relative to the DiR dye. 
The quantum yield for Nile Red is 0.7 [33, 34] compared to 0.25 for DiR [32]. However, 
equally important to the quantum yield would be the fluorescence lifetime, or the time in 
which the fluorophore spends in the excited state before the detected photon is emitted. The 
fluorescence lifetime of Nile Red has been reported to be 4.50 ns [33] and the fluorescence 
lifetime of DiR was 1.1 ns [32]. 
To further investigate the viability of these dye and iron oxide filled microspheres for 
long-term imaging for future in vivo experiments, the Nile Red and iron oxide filled-
microspheres and DiR and iron oxide-filled microspheres were embedded into a 1% agarose 
gel and imaged under the wide-field fluorescence imaging system (CRi Maestro). The 
imaging was done over a period of 2 hrs using continuous light source exposure (503-555 nm 
for Nile Red; 670-710 nm for DiR) and fluorescence measurement acquisition every 60 s. 
Over that time period, the Nile Red and iron oxide-filled microspheres showed a 57% 
decrease in fluorescence intensity as the Nile Red dye (Figure 5.19). However, over that same 
period of time, the DiR and iron oxide-filled microspheres, the fluorescence intensity 
increased by 39% (Figure 5.19). These results indicate that although Nile Red-filled 
microspheres with a higher quantum yield are able to produce higher intensity fluorescent 
images (~40-50x fluorescence intensity difference in the experiments above), compared to 
DiR-filled microspheres; over longer continuous imaging periods, the fluorescence lifetime of 
DiR becomes the more dominant factor allowing for better long-term imaging and decreased 
rates of photobleaching with DiR compared to Nile Red.  
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Figure 5.16: Effect of DiR-filled microspheres concentration on fluorescence intensity. 
Microspheres were made with an oil stock solution of 50 mg/mL iron oxide and 10 mg/mL 
DiR dye. Agarose gels with increasing concentration of DiR-filled fluorescence microspheres 
were measured using the wide-field fluorescence imaging system. The results show a linear 
trend and indicate that the fluorescence signals do not saturate the detection system.   
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Figure 5.17: Effect of Nile Red microspheres concentration on fluorescence intensity. 
Microspheres were made with an oil stock solution of 50 mg/mL iron oxide and 1 mg/mL 
Nile Red dye. Agarose gels with increasing concentration of Nile Red-filled microspheres 
were measured using the wide-field fluorescence imaging system. The results show a linear 
trend followed by a plateau where the Nile Red-filled microspheres saturate the detection 
system.  
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Figure 5.18: Figure 5.17 zoomed in on the range of 0-1.4 x 107 microspheres to better depict 
the linear correlation between concentration of Nile Red-filled microspheres and the measured 
fluorescence intensity. Microspheres were made with an oil stock solution of 50 mg/mL iron 
oxide and 1 mg/mL Nile Red dye.  
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Figure 5.19: Nile Red and iron oxide filled microspheres (blue line) and DiR and iron oxide 
filled microspheres (red line) were embedded into a 1% agarose gel. The gels were imaged 
under the wide-field fluorescence imaging system (CRi Maestro) over a period of 2 hours 
using continuous light source exposure (503-555 nm for Nile Red; 670-710 nm for DiR) and 
fluorescence measurement acquisition every 60 seconds.  
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5.3.2 Loading Capacity of Iron Oxide and Dye 
In order to achieve the ultimate goal of designing a multi-modal contrast agent, the 
needs for high magnetic contrast and high fluorescence contrast must be balanced. Given that 
there was a maximum amount of iron oxide that could be encapsulated into the inner core of 
the protein microspheres as previously described, it is conceivable that the loading of iron 
oxide could potentially displace or affect the loading of dyes into the core of the 
microspheres. Batches of microspheres were synthesized using a constant concentration of 
fluorescent dye (Nile Red or DiR) and increasing concentrations of iron oxide. The first batch 
of microspheres had a constant concentration of 0.5 mg of Nile Red dye/mL of oil and 
increasing concentrations from 0.0 to 50.0 mg/mL of iron oxide in oil. 
The second batch of microspheres had a constant concentration of 5.0 mg/mL DiR 
dye/mL of oil and increasing concentrations from 0.0 to 50.0 mg/mL of iron oxide in oil. The 
protein microspheres were resuspended into a 1% low melting temperature gel agarose at a 
concentration of ~3.8 x 105 microspheres/mL and allowed to solidify in the lid of 35 mm Petri 
dishes. The samples were imaged using the wide-field fluorescence imaging system using the 
same exposure time for all the samples in each batch of microspheres. The Nile Red and iron 
oxide-filled microspheres were excited by a white light source passing through a 503-555 nm 
bandpass filter. The emitted fluorescence from the Nile Red-filled microspheres was filtered 
through a 580 nm long pass filter. The DiR and iron oxide-filled microspheres were excited 
by a while light source passing through a 710-760 nm bandpass filter. The emitted 
fluorescence from DiR-filled microspheres was filtered through an 800 nm long pass filter. 
The presence of iron oxide affected the effective fluorescence signal of the Nile Red 
and DiR differently. In the case of Nile Red-filled microspheres, the measured fluorescence 
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decreased as the concentration of encapsulated iron oxide was increased (Figure 5.20 and 
Figure 5.21). This trend was also observed with the oil stock solution with Nile Red and iron 
oxide, which indicates that the encapsulation into a microsphere likely has little effect on this 
observed trend. One report cited that the increased presence of magnetite in solution with Nile 
Red would change the hydrophobicity of the solution and allow for increased aggregation of 
the particles [35]. This aggregation and decreased hydrophobicity was previously reported to 
be the primary mechanism of the quenching of the Nile Red fluorescence [34, 36, 37]. When 
looking at the absorption spectrum of Nile Red (alone) and Nile Red with iron oxide, the Nile 
Red absorption peak at 525 nm is broadened and relatively lower in intensity above iron oxide 
absorption spectrum (Figure 5.24). Another potential but unlikely cause could be the physical 
displacement of Nile Red by the iron oxide nanoparticles during the microsphere synthesis 
process. However, the same trend of decreasing fluorescence with increased iron oxide 
concentration was also observed the original oil stock solutions prior to encapsulation. 
In the case of the DiR-filled microspheres, the measured fluorescence increased as the 
iron oxide concentration was increased (Figure 5.22 and Figure 5.23). The original oil stock 
solutions used to synthesize the DiR-filled microspheres were also imaged using wide-field 
fluorescence imaging system. The trend of increasing iron oxide concentration correlated to 
increased fluorescence intensities was present for both DiR and iron oxide-filled microspheres 
as well as the original DiR and iron oxide oil stock solution, indicating that this behavior is 
due to the interaction between DiR and the iron oxide. For a constant concentration of DiR, 
the measured fluorescence increased linearly with the concentration of iron oxide. There are 
few reports that have identified dyes complexed with iron oxide that lead to enhanced 
fluorescence and even fewer that describe potential mechanisms. However, 
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superparamagnetic Fe2O3 and Fe3O4 nanoparticles have been complexed with 2-(4-
fluorophenyl)-1-phenyl-1H-phenanthro [9,10-d] imidazole (FPPI) [38]. The authors reported 
the enhanced fluorescence occurred via photo-induced electron transfer (PET), where the 
binding of the dye to the iron oxide nanoparticles lowered the energy levels of the highest 
occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) [38]. 
When compared to the absorption spectrum of Nile Red with iron oxide, the absorption 
spectrum of DiR with iron oxide more closely approximates the shape the sum of the DiR 
absorption spectrum and the iron oxide absorption spectrum. There is also a higher overall 
absorption across the entire spectrum (area under the curve) in the DiR with iron oxide 
absorption spectrum (Figure 5.25). Further fluorescence lifetime experiments need to be 
performed to determine the effects of iron oxide binding to DiR has on the fluorescence 
lifetime and decay rates of DiR. 
  
  159 
 mg of Nile Red/mL of oil mg of iron oxide/mL of oil Fluorescence Image 
Agarose Gel with 
Protein Microspheres 
0.0 0.0 
 
Agarose Gel with 
Protein Microspheres 
0.5 0.0 
 
Agarose Gel with 
Protein Microspheres 
0.5 12.5 
 
Agarose Gel with 
Protein Microspheres 
0.5 25.0 
 
Agarose Gel with 
Protein Microspheres 
0.5 37.5 
 
Agarose Gel with 
Protein Microspheres 
0.5 50.0 
 
Agarose Gel without 
Protein Microspheres 
N/A N/A 
 
 
Figure 5.20: Protein microspheres synthesized with the same concentration of Nile Red dye 
and increasing concentrations of iron oxide nanoparticles at the time of synthesis.  
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Figure 5.21: Relative fluorescence intensities of agarose gel phantoms of a series of protein 
microspheres with increasing concentration of encapsulated iron oxide nanoparticles and 
constant concentration of Nile Red dye.  
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 mg of DiR/mL of oil mg of iron oxide/mL of oil Fluorescence Image 
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Agarose Gel without 
Protein Microspheres 
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Figure 5.22: Protein microspheres synthesized with the same concentration of DiR dye and 
increasing concentrations of iron oxide nanoparticles at the time of synthesis. 
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Figure 5.23: Relative fluorescence intensities of agarose gel phantoms of a series of protein 
microspheres with increasing concentration of encapsulated iron oxide nanoparticles and 
constant concentration of DiR dye.  
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Figure 5.24: Absorption spectra of the vegetable oil (1), Nile Red mixed in the oil (2), iron 
oxide mixed in the oil (3), and Nile Red and iron oxide mixed together in the oil (4). Spectra 2 
and 3 were added together to reflect the theoretical absorption spectrum of a mixed solution of 
Nile Red and iron oxide since absorption is normally an additive process.  
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Figure 5.25: Absorption spectra of the vegetable oil (1), DiR mixed in the oil (2), iron oxide 
mixed in the oil (3), and DiR and iron oxide mixed together in the oil (4). Spectra 2 and 3 
were added together to reflect the theoretical absorption spectrum of a mixed solution of DiR 
and iron oxide since absorption is normally an additive process.  
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5.4 Conclusions 
The magnetic properties of iron oxide-filled protein microspheres were characterized 
using MM-OCT and MRI. The results from each modality are in agreement with each other. 
Both methods are able to quantify the concentration of iron oxide-filled protein microspheres. 
The fluorescence properties of DiR-filled microspheres and Nile Red-filled microspheres 
were characterized and quantified using the wide-field fluorescence imaging system. The 
integrity of the optical properties of the DiR and Nile Red dyes through the microsphere 
synthesis process was assessed by monitoring changes to both the excitation and emission 
peaks of DiR and Nile Red. By making modifications to the encapsulation protocol of DiR 
such as the solvent used to initially dissolve the DiR, and the temperature at which the solvent 
was evaporated, the fluorescence properties of DiR were maintained (Figure 5.13). The 
microspheres could be detected and quantified under MM-OCT, MRI, and wide-field 
fluorescence imaging in gel samples. The maximum loading capacity of iron oxide into the 
inner core of microspheres was determined using MRI data. However, the assumption was 
made that encapsulation of the iron oxide with oil would have minimal effect on the relaxivity 
of the iron oxide since in both cases the iron oxide was still suspended in the oil and was not 
shown to heavily aggregate (Figure 4.9) under TEM images. The presence of iron oxide 
appears to have quenched the Nile Red fluorescence likely due to Nile Red’s sensitivity to 
changes in the hydrophobicity and polarity of the microenvironment. The enhanced 
fluorescence of DiR by iron oxide is a phenomenon that needs to be studied further 
mechanistically though others have reported enhanced fluorescence with iron oxide 
nanoparticles due to photo-induced energy transfer. 
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CHAPTER 6 
IN VITRO TARGETING OF PROTEIN MICROSPHERES IN CANCER 
6.1 Introduction 
Layer-by-layer (LBL) assembly is a versatile technique for depositing or layering of 
thin films on particles or surfaces for a wide variety of applications including biosensing, drug 
delivery, and tissue engineering. The focus in this chapter will be on the use of the LBL 
technique to target the protein microsphere to the αvβ3 integrin receptor using the RGD motif. 
The use of core-shell particles and capsules such as liposomes, protein microspheres, polymer 
micelles, and dendrimers is advantageous for targeted drug delivery applications [1-8]. These 
core-shell particles can potentially encapsulate large therapeutic payloads while providing a 
protective shell increasing their circulation time and bypassing the normal clearance of the 
drugs by the body. These particles are also capable of encapsulating not just a single drug but 
also multiple drugs similar to how we are encapsulating multiple contrast agents into a single 
protein microsphere. This type of research would help further advance the research field for 
targeted multi-drug therapy. 
The targeting of core-shell particles and capsules ranging in size from 20 nm to 3 µm 
can be accomplished using LBL assembly to functionalize the outer surface with ligands such 
as RGD peptides or specific antibodies [8-18]. It was recently demonstrated that 800 nm-sized 
capsules made of poly (N-vinyl pyrrolidone) could be functionalized with azide-
functionalized antibodies using LBL and successfully targeted [19]. The protein microspheres 
described in this thesis have also been functionalized with RGD peptide sequences using LBL 
for targeting HT-29 tumor cells [20]. In Chapter 4, the LBL assembly method was used to 
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layer PDDA, silica, and RGD on to the protein microspheres surface for in vitro and in vivo 
applications. More recently, a targeted nanoparticle was developed using LBL assembly 
where the outer layer would be degraded once it reached the target site [16]. In this particular 
report, the PEG layer was shed based on the acidity of the tumor microenvironment [16]. 
With the recent research advances using the LBL assembly, there are many opportunities to 
further customize the contrast, therapeutic, and targeting properties of the protein 
microsphere. In addition to encapsulating contrast agents in the inner core as previously 
described in Chapter 4, layers of contrast agents can be deposited on the microsphere surface 
using LBL. The functionality of the microsphere can also be altered through the addition of 
different particles such as the addition to silica to precipitate the microspheres for in vitro 
experiments, or adding a PEG coating to increase the in vivo circulation of microspheres. 
The LBL assembly method previously described in Chapter 4 depends on the 
adsorption of alternating charged particles. For example, in the case of the protein 
microspheres described in this thesis, the surface of the BSA protein shell provides a 
negatively charged surface. The PDDA or the RGD poly-lysine peptide sequence can both be 
individually layered directly onto the bare surface of the protein microspheres since both have 
large positively charged domains. To layer negatively charged silica on top of the protein 
microspheres, the protein microspheres must first be coated by a positively charged layer such 
as PDDA to reverse the charge on the surface from negative to positive. Due to the 
electrostatic interactions, the layering of the particles is fairly uniform in distribution, forming 
thin films across the surface of the core-shell particle. 
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6.1.1 Previous Studies on Layering of Protein Microspheres using RGD sequence 
The RGD peptide was previously layered to the surface of protein microspheres using 
the LBL assembly method [20]. Since RGD is not highly positively charged, a poly-lysine 
sequence was attached to the RGD sequence in order to take advantage of the LBL method to 
layer the RGD sequence onto the surface of protein microspheres. The effect of placing the 
RGD sequence at different locations of the poly-lysine sequence was investigated to 
determine which sequence provided the greatest binding to HT-29 cells [20]. The RGD 
sequence was placed on the amino terminus (RGDKKKKKK), in the middle 
(KKKRGDKKK), and on the carboxyl terminus (KKKKKKRGD). The sequence that best 
secured the RGD-coated microsphere to the cell surface was when the RGD was placed on the 
amino terminus [20]. These initial findings allowed us to use this construct as the basis to 
further study the binding specificity and cellular uptake of the RGD-coated protein 
microspheres to the αvβ3 integrin receptor, which is often overexpressed in metastatic cancer 
cells and tumor angiogenesis. 
6.1.2 Initial Studies using RGD-coated Protein Microspheres 
Preliminary experiments were repeated to confirm the successful synthesis of      
RGD-coated protein microspheres. The RGD-coated and non-coated microspheres were 
incubated with HT-29 cancer cells for two hours and washed with PBS to remove any excess 
unbound microspheres. The HT-29 cell line is a colon cancer cell line that is known to have 
an overexpression of the integrin receptors [21-23]. After the 2 hrs incubation, the cells were 
washed with phosphate buffer saline three times and imaged using a light microscope. The 
light microscopy images shown in Figure 6.1 confirmed the results previously reported by 
Toublan [20]. The higher binding affinity of the HT-29 cells to the RGD-coated protein 
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microspheres can be clearly seen when compared to the non-coated protein microspheres. 
Although the RGD-coated microspheres attached and remained bound to the HT-29 cells, 
little was known about the binding mechanism and the cellular uptake of microspheres. This 
chapter will examine the correlation between the binding specificity of RGD-coated protein 
microspheres to various cancer cell lines and the αvβ3 integrin receptor expression level of the 
cells. Time-lapse fluorescence microscopy studies will also be discussed to gain insights on 
the cellular uptake mechanism of targeted and non-targeted protein microspheres. 
 
 
(a)  
(b)  
 
Figure 6.1: Brightfield images of HT-29 cells at 10X after they have been incubated for two 
hours with non-targeted (a) and targeted (b) protein microspheres.  
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6.2 Quantifying the Expression of αvβ3 Integrin Receptors on Cells using Indirect 
Immunofluorescence Staining and Flow Cytometry 
To gain a better understanding about the targeting specificity of the RGD-coated 
protein microspheres to αvβ3 integrin receptors expressed on cancer cell lines, a panel of 
cancer cell lines with differing levels of receptor expression were examined. Absolute 
quantification of αvβ3 integrin receptors expressed on the cell surface can be measured by 
flow cytometric analysis of cells labeled with fluorochrome-coupled monoclonal antibodies 
specific to the alpha and beta subunits of the integrin receptor. However, this method is not 
without limitations when used to evaluate binding of the protein microspheres to these 
receptors, and it may be more relevant to compare relative trends between different cell lines 
rather than absolute numbers. Specifically, SEM characterization of the RGD-coated protein 
microspheres revealed that the microspheres do not appear to be uniformly and completed 
coated with RGD peptides (Figures 4.3-4.8). If the coverage of the microsphere surface by 
RGD peptides is not uniform or not completely covered, the orientation of the microsphere 
relative to the binding site now becomes an issue. In addition, the overall size of microspheres 
(1-3 µm) is relatively large compared to monoclonal antibodies (~5-10 nm) and the average 
cell sizes of 10-15 µm. This size difference may physically constrain access for additional 
microspheres but not the antibodies to bind nearby integrin receptors exposed on the cell 
surface. Lastly, compared to fluorescence microscopy, which examines cells that are attached 
to the bottom of Petri dishes, the entire cell surface is exposed during flow cytometry. This is 
important because significant populations of integrin receptors, which mediate cell-substrate 
adhesion, are likely present at the junction between the cells and the bottom of the culture dish 
rather than exposed on the apical side of the cells, exposed to the overlying culture medium. 
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Given all of these factors, it is more important to measure the relative expression of the 
integrin receptors on the cell surface or the binding of the receptor by the microsphere 
between different cell lines. 
For the flow cytometric study of αvβ3 integrin receptor expression on various cancer 
cell lines listed in Figure 6.4 and Figure 6.5, confluent monolayers of cells were cultured in 
Petri dishes. The cells were washed with warm (37°C) sterile PBS three times to ensure the 
complete removal of cell culture medium. The cells were trypsinized with 1X trypsin (0.05% 
Trypsin + 0.2 g / L EDTA 0.85 g / L NaCl). After about 10-15 minutes, the cells detached 
from the bottom of the cell culture dishes. The cells were diluted in their respective culture 
medium to rapidly deactivate the trypsin. The cells were centrifuged at 1500 RPM for 5 mins 
and resuspended in culture medium. The cells were spun down once more to remove any 
residual trypsin. The cells were resuspended in sterile PBS and counted using a 
hemocytometer. Four aliquots of 1 x 106 cells (one negative staining control and three positive 
controls) for each cell line were prepared into 1.5 mL Eppendorf tubes. Throughout the 
procedure, it was important to keep the cells on ice in order to maintain their viability. 
The cells were washed twice by resuspension in cold PBS buffer solution (1X PBS, 
1% BSA, 0.5 mM EDTA) and centrifugation at 6000 RPM for 5 mins. The primary αvβ3 
antibody (mouse monoclonal IgG1, GeneTex cat. #GTX4013) was added to each of three cell 
aliquots marked for positive staining at a concentration of 1 µg / 1 x 106 cells. This step labels 
exposed αvβ3 integrin receptors on the cell surface. The cells were incubated in this solution at 
4°C on an orbital shaker set at ~200 RPM for 30 minutes. 
Cells were washed twice with cold buffer solution, as previously described. At this 
point, all overhead lights were turned off to prevent photobleaching of the light-sensitive 
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fluorescence tags. The secondary antibody (anti-mouse conjugated with FITC) was added to 
all four aliquots of cells at a concentration of 1 µg / 1 x 106 cells. The samples were covered 
with foil and placed on an orbital shaker at ~200 RPM and incubated at 4°C for 30 minutes. 
The cells were washed twice with cold buffer solution and then resuspended in 300 µL of the 
cold buffer solution. The cells were maintained on ice and covered with foil until they could 
be analyzed by flow cytometry. 
The flow cytometry facilities at the Roy J. Carver Biotechnology Center at the 
University of Illinois at Urbana-Champaign were used for these experiments. The flow 
cytometer was a BD Biosciences LSR II system. Before each experiment, passing a bleach 
solution through the flow channel cleaned the instrument. The first step involved taking 
measurements of FITC fluorescent bead standards (Bang Laboratories, #555A, Quantum 
FITC-5 MESF). There were five different standards in this particular kit of five populations of 
7-9 µm beads, each with different levels of FITC fluorescence intensities per bead. 
Comparison of stained samples to the standards allowed quantification of fluorescent particles 
per scattering particle (the cell) through the flow channel. 
A standard curve (Figure 6.3) was generated by plotting the channel number at which 
the fluorescence intensity peaked against the known values measured and calibrated by Bangs 
Laboratories. Next, the stained cell samples were measured using the flow cytometer. Ten 
thousand scattering events (or cells) were collected for each aliquot (triplicate positive 
staining controls and one negative control). The data were analyzed using FCS Express 
software (DeNovo Software). Each data set was initially gated in a plot of the forward 
scattering against the side scattering signal in order to exclude non-cellular particles. A 
second gating was made to isolate live cells versus dead cells by plotting the forward 
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scattering width against the forward scattering amplitude. The resulting FITC intensity 
fluorescence peak was identified using the median channel value. These channel values were 
converted to MESF/ABC values using the standard curve previously established. The 
MESF/ABC corresponds to the measured fluorescence intensity per cell. The MESF/ABC 
values for the positively stained cells were subtracted by the MESF/ABC values of the 
negative controls. The resulting values were averaged across triplicate samples for each cell 
line. These values are reported as the number of αvβ3 integrin molecules per each cell  
(Figures 6.5-6.6). The flow cytometry data were also re-analyzed to examine the ratio of 
specific binding (positively stained minus negatively stained) to non-specific binding 
(negatively stained) to more easily compare the expression results from flow cytometry to the 
fluorescence microscopy data of the targeting of the RGD-coated protein microspheres in 
vitro. 
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Figure 6.2: Flow cytometry measurements of the FITC intensities from five standard beads 
used to correlate the measured FITC fluorescence intensities to the absolute number of 
fluorophores. 
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Figure 6.3: Standard curve of FITC fluorescent bead standards used to calibrate fluorescence 
intensity measurements from the flow cytometer. The mean equivalent of soluble 
fluorochrome (MESF) per antibody binding capacity (ABC) is plotted against the 
fluorescence intensity channel. 
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Cell Line ATCC # Description 
MAT III 13762 CRL-1666 Rat – Mammary Gland – Adenocarcinoma – Epithelial 
HT-29 HTB-38 Human – Colon – Colorectal Adenocarcinoma – Epithelial 
SK-BR-3 HTB-30 Human – Mammary Gland – Breast – Adenocarcinoma – Epithelial 
MCF-7 HTB-22 Human – Mammary Gland – Breast – Adenocarcinoma – Epithelial 
hTERT-HME1 CRL-4010 Human – Mammary Gland – Breast – Immortalized – Epithelial 
HCC38 CRL-2314 Human – Mammary Gland – Breast – Primary Ductal Carcinoma – 
Epithelial 
ZR-75-1 CRL-1500 Human – Mammary Gland – Breast – Ductal Carcinoma – Epithelial 
 
Figure 6.4: Flow cytometric analysis quantified the αvβ3 integrin receptor expression on a 
panel of cancer cell lines available in Prof. Boppart’s laboratory. These results demonstrate 
that aside from the HCC38 cell line, the majority of the cell lines had relatively little active 
expression of the αvβ3 integrin receptor at the time the studies were performed.  
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The results suggest that flow cytometry is a suitable method for quantifying αvβ3 
integrin receptor expression on cells. Between two sets of measurements taken approximately 
six months apart, the trends are fairly similar aside from one cell line (HCC38). Although as 
much as possible was done to ensure that the same conditions and protocols were used, many 
factors could alter expression levels of the integrin receptors. These factors include: the 
confluence levels of the cells, the passage number of the cells, the day to day variations of the 
flow cytometer, and other factors that may affect the health of the cell and the integrity of the 
receptor. 
After the first set of results (Figure 6.4) was analyzed, two new breast cancer cell lines 
(MDA-MB-231 and MDA-MB-435S) were acquired. These particular cell lines are well 
characterized as highly metastatic and have also been used effectively by others for the study 
of cancer metastasis in mice models [24-26]. As shown in Figure 6.5, the expression levels of 
these two cell lines are several times higher than those of the other cell lines available in Prof. 
Boppart’s laboratory.  
Currently, our laboratory uses two main animal tumor models. The first is an            
N-nitroso-N-methylurea (NMU) carcinogen induced tumor animal model that produces 
spontaneous tumors 8-10 weeks after injecting NMU carcinogen into the animal. The second 
model is induced by injecting MAT III 13762 cell lines sub-cutaneously to form primary 
tumors. The quantification of the integrin receptor expression of the cell lines could help 
dictate which cell lines would be most effective in a xenograft tumor model to test the in vivo 
targeting of protein microspheres (Figures 6.5-6.6). 
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Cell Line ATCC # Description 
HT-29 HTB-38 Human – Colon – Colorectal Adenocarcinoma – Epithelial 
SK-BR-3 HTB-30 Human – Mammary Gland – Breast – Adenocarcinoma – Epithelial 
MCF-7 HTB-22 Human – Mammary Gland – Breast – Adenocarcinoma – Epithelial 
hTERT-HME1 CRL-4010 Human – Mammary Gland – Breast – Immortalized – Epithelial 
HCC38 CRL-2314 Human – Mammary Gland – Breast – Primary Ductal Carcinoma – 
Epithelial 
ZR-75-1 CRL-1500 Human – Mammary Gland – Breast – Ductal Carcinoma – Epithelial 
MDA-MB-231 HTB-26 Human – Mammary Gland – Breast – Adenocarcinoma – Epithelial 
MDA-MB-435S HTB-129 Human – Mammary Gland – Breast – Ductal Carcinoma – spindle 
shaped 
 
 
Figure 6.5: Flow cytometry results of αvβ3 integrin expression on the cancer cell lines from 
Figure 6.4 and two highly metastatic cell lines, MDA-MB-231 and MDA-MB-435S. High 
expression levels of αvβ3 integrin receptors closely corresponded with the cell metastatic 
behavior [27-31]. 
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(a)  
(b)  
 
Figure 6.6: Flow cytometry results expressed as an absolute values (a) and as a ratio of 
specific binding [ (+) stain – (-) stain) ] to non-specific binding [ (-) stain ] (b). Representing 
the data in this format allows a more direct comparison to the fluorescence microscopy data 
that will be presented later in this chapter. Compared to Figure 6.5, there is a lower level of 
non-specific binding in the MDA-MB-435S cell line compared to the MDA-MB-231 cell line.  
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6.3 Targeting of the RGD-coated Microspheres to the αvβ3 Integrin Receptor In Vitro 
Protein microspheres with encapsulated Nile Red dye were used for fluorescence 
imaging experiments to assess the targeting of the microspheres to αvβ3 integrin receptors 
expressed on various cell lines. Using the LBL adhesion method, microspheres were coated 
with a layer of PDDA followed by a layer of silica. One batch of microspheres was 
additionally coated with a layer of RGDKKKKKK, and a second batch of microspheres 
remained uncoated at the silica layer. Approximately 100,000 cells from each cancer cell line 
(HT-29, SK-BR 3, MCF-7, hTERT-HME1, ZR-75-1, MDA-MB-231, MDA-MB-435S) were 
seeded into each well of a 4-well chamber slide. The HT-29 cell line, a colon cancer cell line, 
was chosen to correlate results with previous data from Prof. Suslick’s laboratory [7, 20]. The 
MCF-7 cell line was chosen as a negative control since it has a low to no expression of the 
αvβ3 integrin receptor [32]. The MDA-MB-231 and MDA-MB-435S cell lines are highly 
metastatic breast cancer cell lines overexpressing the αvβ3 receptor [32]. The remaining breast 
cancer cell lines were chosen to provide a spectrum of αvβ3 receptor expression levels. 
The expression of this receptor has been highly associated with more aggressive and 
metastatic cancers different organ systems [33]. With increased expression of αvβ3 receptor, 
the cell is more likely to migrate, invade into nearby tissue by adhesion into the extracellular 
matrix, and as a promoter for angiogenesis [32-35]. As the vascular requirements of the 
cancer cell or tumor increases, so does the expression of αvβ3 receptor [34]. When contrasting 
in vitro versus in vivo expression of the αvβ3 receptor, multiple variables will come into play 
including but not limited to: confluence or density of the cancer cells or mass, the cell’s 
ability to adhere to a surface or another cell versus exposed to free air, the availability of 
nutrients, the cell cycle stage and associated metabolic demand of the cancer cell, etc. Hence, 
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it was important in vitro to ensure that cells were in seeded in a high enough concentration 
and cultured into monolayers of cells to promote a greater expression of the αvβ3 receptor. 
The seeding density of the cell cultures used was about 50% confluence to allow the 
cells to form a uniform monolayer of cells within 24 hours. By having this monolayer, the 
microspheres can interact directly with the cell surface decreasing the background signal due 
to microspheres adherent to the bottom of the Petri dish. Microspheres attached to the bottom 
of the dishes were very difficult to remove and required at least 5-10 PBS washes increasing 
the chances that the cells would also be washed off in the process. The cells were allowed to 
attach to the chamber slide for 24 hours. The cells were then washed three times with sterile 
PBS to remove any floating or dead cells. For each cell line, two of the four wells were 
incubated with RGD-coated Nile Red-filled microspheres. The other two wells were 
incubated with non-coated Nile Red-filled microspheres. The microspheres were first 
resuspended into culture medium at a concentration of ~40,000 microspheres / mL of media. 
Each well in the chamber slide was incubated with 1 mL of the microsphere solution for 1 hr. 
After the incubation period, cells were washed twice with sterile PBS to remove any excess or 
unbound microspheres. Cell cultures were resuspended with culture medium until the time of 
imaging. During fluorescence imaging, the cell medium was removed and PBS was added to 
reduce background fluorescence coming from the cell medium. Multidimensional acquisition 
of both fluorescence and brightfield images was taken using a 20X objective on a Zeiss 
Axiovert 200 inverted microscope. Images were acquired at ten different locations with 
similar densities of cells for each sample. Images in the fluorescence channel were taken 
using the auto-exposure setting to take advantage of the full dynamic range of the detection 
system and to reduce the chances of saturating the camera. 
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The fluorescence images were overlayed on top of their respective brightfield images 
to better visualize the localization of Nile Red dye that was initially encapsulated in the 
protein microspheres. The effective exposure time of the processed fluorescence images was 
normalized to allow for visual comparison of fluorescence intensities between RGD-coated or 
non-coated microspheres bound to different cell lines. The fluorescence intensity signals from 
the rescaled images were averaged over the entire image using ImageJ software (NIH, 
Version 1.45) and ten images were averaged for each cell type. 
The percent increase in fluorescence was calculated by comparing average 
fluorescence intensities of RGD-coated vs. non-coated microspheres bound to each cell line 
[(+) RGD-µspheres – (-) RGD-µspheres] / [(-) RGD-µspheres] (Figure 6.14). This is the ratio 
of specific binding of the RGD-coated microspheres to the non-specific binding of the non-
coated microspheres to the αvβ3 integrin receptors. The fluorescence data from the MCF-7 and 
hTERT-HEM1 cell lines were not included in Figure 6.14 as the difference between the 
average fluorescence intensities of the RGD-coated and non-coated microspheres fell within 
the error of the averages. The results of the fluorescence imaging experiments correlate well 
with the flow cytometry results. The two metastatic cell lines (MDA) that were the highest 
expressers of surface integrin receptors as measured by flow cytometry were also bound with 
the highest amount of RGD-coated microspheres as determined by fluorescence imaging. The 
fluorescence intensity values was calculated as the average fluorescence intensity across the 
entire image and does not make a distinction between the discrete bright spots corresponding 
to intact microspheres and diffuse areas of fluorescence corresponding to Nile Red in the cell 
cytoplasm after the microsphere has been internalized and ruptured by the cell. Hence, no 
conclusions can be made regarding the time course of the microsphere binding, uptake, and 
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rupture as separate entities with this particular data. Although the relative trends across the 
cell lines are in agreement, there are several reasons to be cautious in directly comparing the 
two. The flow cytometry data uses specific monoclonal antibodies targeted to the αvβ3 integrin 
receptor compared to the RGD on the microspheres, which generally target the αvβ3 integrin 
receptor but can also non-specifically bind to other cell surface receptors. The flow cytometry 
data also is able to assess the entire surface area of the cell, compared to the fluorescence 
microscopy data, where only the exposed cell surface not adhered to the bottom of the Petri 
dish is assessed. Cell-to-cell or cell-to-surface tension plays an important role in the 
expression of the integrin receptors and likely affect the physical distribution of the surface 
receptors [32, 33]. With an average cell size of approximately 15 µm, the surface area of the 
average cell is approximately 706.5 µm2. With an average microsphere size of 1-2 µm 
covering an area of 1-4 µm2, the maximum number of microspheres that could cover a cell 
would be between 175 – 700 microspheres per cell assuming that the availability of integrin 
receptors was not a limiting factor and that the microspheres could form a uniform layer. 
For each cell line, the fluorescence images for the RGD-coated microspheres were 
higher in intensity compared to the non-coated microspheres. In most of the images, small, 
discrete, bright spots corresponded to intact microspheres (Figures 6.7-6.13). Diffuse 
fluorescence signals localized within cells suggested that microspheres were engulfed and 
broken down by the cell (Figures 6.7-6.13). Although no direct cell viability stains were done 
to assess the cells after being incubated with protein microspheres, it was noted that the cells 
were able to survive and continue replicating for at least 24 hours after incubation and upon 
prompt cell media replacement after the initial exposure to the microspheres. Further 
experiments were performed using a confocal microscope (Leica SP2 Visible Laser Confocal 
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Microscope) in the Beckman Institute for Advanced Science and Technology Microscopy 
Suite to confirm the location of the microspheres and the Nile Red dye. The cells were stained 
with DiO perchlorate (AAT Bioquest #22066), a lipophilic dye that stains the phospholipid 
cell membrane, and the cells reseeded at a high concentration into Petri dishes to quickly form 
a cell monolayer. The cells were kept in the incubator at 37°C for 4 hours to allow the cells to 
firmly adhere to the Petri dish surface and placed inside a foil wrap to prevent any potential 
photobleaching of the DiO dye. The microspheres used for these experiments contained Nile 
Red dye in the inner core. The microspheres were mixed in with the media, placed over cell 
monolayer, and confocal imaging was started immediately. After the first set of confocal 
images (~5 minutes) were taken, the cells were gently washed with PBS three times similar to 
the previous experiments, and imaged over a 30 min period. Using time lapsed imaging, the 
images demonstrate that the protein microspheres initially start as bright, discrete, and intact 
fluorescent spheres to eventually being diffused across the entire cell volume (Figure 6.15). In 
comparing the RGD-coated Nile Red-filled microspheres to the non-coated Nile Red-filled 
microspheres (Figure 6.16), the non-coated microspheres appear to stay attached to the cell 
surface as intact microspheres. Whereas in the case of RGD-coated microspheres, the 
fluorescence from the Nile Red can be seen in the cell cytoplasm at significantly higher 
intensities. This would be consistent with previous reports that RGD binding to the αvβ3 
integrin receptor induces endocytosis of the attached ligands [35, 36]. Additional discussion 
on the uptake of microspheres by cells is in the next section. Confocal microscopy confirms 
the results observed under fluorescence microscopy: there is binding and uptake of protein 
microspheres by these cancer cells and there is preferential uptake of the RGD-coated protein 
microspheres over non-coated protein microspheres.  
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Figure 6.7: Fluorescence images of HT-29 cells incubated with RGD-coated and with non-
coated Nile Red-filled microspheres after a 1 hr incubation period. The fluorescence images 
(right column) are normalized to the same effective exposure time. The fluorescence images 
overlayed on the brightfield images (left column) have not been normalized for viewing 
purposes. Bright discrete spots are intact protein microspheres (blue arrow). Diffuse 
fluorescence (green arrow) across the surface of the cell indicates binding, uptake, and 
degradation of the microsphere.  
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Figure 6.8: Fluorescence images of SK-BR-3 cells incubated with RGD-coated and with non-
coated Nile Red-filled microspheres after a 1 hr incubation period. The fluorescence images 
(right column) are normalized to the same effective exposure time. The fluorescence images 
overlayed on the brightfield images (left column) have not been normalized for viewing 
purposes. Bright discrete spots are intact protein microspheres (blue arrow). Diffuse 
fluorescence (green arrow) across the surface of the cell indicates binding, uptake, and 
degradation of the microsphere.  
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Figure 6.9: Fluorescence images of MCF-7 cells incubated with RGD-coated and with non-
coated Nile Red-filled microspheres after a 1 hr incubation period. The fluorescence images 
(right column) are normalized to the same effective exposure time. The fluorescence images 
overlayed on the brightfield images (left column) have not been normalized for viewing 
purposes. Bright discrete spots are intact protein microspheres (blue arrow). Diffuse 
fluorescence (green arrow) across the surface of the cell indicates binding, uptake, and 
degradation of the microsphere.  
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Figure 6.10: Fluorescence images of hTERT-HME1 cells incubated with RGD-coated and 
with non-coated Nile Red-filled microspheres after a 1 hr incubation period. The fluorescence 
images (right column) are normalized to the same effective exposure time. The fluorescence 
images overlayed on the brightfield images (left column) have not been normalized for 
viewing purposes. Bright discrete spots are intact protein microspheres (blue arrow). Diffuse 
fluorescence (green arrow) across the surface of the cell indicates binding, uptake, and 
degradation of the microsphere.  
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Figure 6.11: Fluorescence images of ZR-75-1 cells incubated with RGD-coated and with non-
coated Nile Red-filled microspheres after a 1 hr incubation period. The fluorescence images 
(right column) are normalized to the same effective exposure time. The fluorescence images 
overlayed on the brightfield images (left column) have not been for viewing purposes. Bright 
discrete spots are intact protein microspheres (blue arrow). Diffuse fluorescence (green arrow) 
across the surface of the cell indicates binding, uptake, and degradation of the microsphere.  
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Figure 6.12: Fluorescence images of MDA-MB-231 cells incubated with RGD-coated and 
with non-coated Nile Red-filled microspheres after a 1 hr incubation period. The fluorescence 
images (right column) are normalized to the same effective exposure time. The fluorescence 
images overlayed on the brightfield images (left column) have not been normalized for 
viewing purposes. Bright discrete spots are intact protein microspheres (blue arrow). Diffuse 
fluorescence (green arrow) across the surface of the cell indicates binding, uptake, and 
degradation of the microsphere.  
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Figure 6.13: Fluorescence images of MDA-MB-435S cells incubated with RGD-coated and 
with non-coated Nile Red-filled microspheres after a 1 hr incubation period. The fluorescence 
images (right column) are normalized to the same effective exposure time. The fluorescence 
images overlayed on the brightfield images (left column) have not been normalized for 
viewing purposes. Bright discrete spots are intact protein microspheres (blue arrow). Diffuse 
fluorescence (green arrow) across the surface of the cell indicates binding, uptake, and 
degradation of the microsphere.  
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 (a)  
(b)  
Figure 6.14: The percentage increase in the average fluorescence intensity of cells incubated 
with RGD-coated microspheres compared to cells incubated with non-coated microspheres 
[(+) RGD-µspheres – (-) RGD-µspheres] / [(-) RGD-µspheres], as measured by fluorescence 
microscopy (a). Corresponding flow cytometry results of the integrin receptor expression 
levels shows a similar trend to the fluorescence imaging results (b). 
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MDA-MB-231 Cell Line w/ non-targeted Nile Red-filled microspheres 
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Figure 6.15: The MDA-MB-231 metastatic breast cancer cell line was incubated with non-
targeted Nile Red-filled protein microspheres. There are initially distinct bright protein 
microspheres (blue) which progress to the diffuse staining of the entire cell cytoplasm 
(yellow) with smaller aggregates of Nile Red dye (white) seen after 30 minutes. 
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MDA-MB-435S Cell Line w/ non-targeted and targeted (RGD) Nile Red-filled microspheres 
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Figure 6.16: The MDA-MB-435S metastatic breast cancer cell line was incubated with non-
targeted and targeted (RGD) Nile Red-filled protein microspheres for 30 mins. The non-
targeted microspheres (blue: discrete bright intact spheres) remain largely adhered to the cell 
membrane compared to the targeted (RGD) microspheres have been internalized into the cell 
and stain the cell cytoplasm at much brighter intensities (yellow).  
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6.4 In Vitro Uptake of Microspheres by Cancer Cells 
After the successful targeting of microspheres to the integrin receptor, the observation 
made in the previous study that microspheres could be engulfed by various cell lines raised 
interest in the cellular uptake mechanism of the microspheres. As described in the previous 
studies, intact microspheres were observed as discrete, bright spots; whereas, diffuse 
fluorescence signal throughout the entire surface area of cells suggested that the microspheres 
were engulfed and broken down by the cells. The relatively large size of the microspheres 
suggested that they would, be endocytosed if engulfed by cells. In addition, several published 
reports suggest that ligands bound to the αvβ3 integrin receptor itself may induce endocytosis 
of the attached ligand [35, 36]. Given that microspheres are an average of 1-3 µm in size, the 
most likely method of endocytosis is phagocytosis, which is used by cells to ingest the larger 
particulates. Phagocytosis can be undertaken by epithelial cells as previously reported in 
respiratory epithelial cells for microspheres that are 2-3 µm in size [37]. 
Initial studies of the cell uptake mechanism examined incubation of MCF-7 and 
MDA-MB-435S cells with RGD-coated and non-coated Nile Red-filled microspheres. The 
cells were examined at four different time points: 15, 30, 45, and 60 minutes. The cells were 
incubated for each of those time intervals, washed twice with PBS, and imaged with the 
fluorescence microscope, as previously described. The fluorescence data were similarly 
processed and are presented in Figures 6.17-6.20. In the first two figures (Figures 6.17-6.18), 
the fluorescence intensity averages were normalized to the 1 hr time point for each respective 
cell line. For the following two figures (Figures 6.19-6.20), the fluorescence intensity 
averages were normalized to the maximum value of both the RGD-coated and non-coated 
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cases. This would allow for the direct comparison of the binding and uptake of the RGD-
coated and non-coated microspheres for each cell line. 
The uptake dynamics of both RGD and non-coated microspheres appeared to follow 
the same time scale. At 30-45 minute incubation period, the binding and uptake of the 
microspheres by the cell was saturated as demonstrated in Figures 6.17-6.20. At later time 
points, no appreciative increase in the uptake of the microspheres by the cells is seen. The use 
of a one hour incubation time period was appropriately chosen for the previous study to look 
at the binding specificity of the microspheres by the cancer cells. From Figure 6.19 and Figure 
6.20, the preferential binding and uptake of the RGD-coated microspheres over the non-
coated microspheres is readily apparent with the MDA-MB-435S cells and is not noticeable 
with the MCF-7 cells. These results correlate with the previous flow cytometry results, which 
indicated that minimal expression of the αvβ3 in MCF-7 cells and a significant overexpression 
of the receptor in the MDA-MB-435S cells. 
Fluorescence images of cells incubated with the microspheres revealed that the Nile 
Red dye is no longer confined to individual microspheres but stained the entire cell. The 
cancer cells are believed to uptake the microspheres by endocytosis and break down the 
microsphere releasing the encapsulated Nile Red. Further studies are needed to monitor in real 
time, without photobleaching the dyes, exactly how the cell internalizes the microspheres 
after binding and how the cell degrades the microspheres.  
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Figure 6.17: Time-lapse study of the binding and uptake of RGD-coated microspheres by the 
MCF-7 and MDA-MB-435S cells. Fluorescence signals were normalized to the 1 hr time 
point for each respective cell line. The maximum binding and uptake of the microspheres by 
the cells is reached at the 45 mins time point.  
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Figure 6.18: Time-lapse study of the binding and uptake of non-coated microspheres by the 
MCF-7 and MDA-MB-435S cells. Fluorescence signals were normalized to the 1 hr time 
point for each respective cell line. The maximum binding and uptake of the microspheres by 
the cells is reached at the 45 mins time point.  
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Figure 6.19: Time-lapse study of the binding and uptake of RGD and non-coated 
microspheres by MCF-7 cells. In the first 15 mins, the RGD-coated microspheres seem to 
preferentially bind to the MCF-7 cells. After 30 mins, there is little to no noticeable 
preferential binding of RGD-coated by the MCF-7 cells.  
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Figure 6.20: Time-lapse study of the binding and uptake of RGD-coated and non-coated 
microspheres by MDA-MB-435S cells. Throughout all four incubation time points, the results 
demonstrate that MDA-MB-435S cells have a stronger binding affinity for the RGD-coated 
microspheres over the non-coated microspheres.  
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6.5 Conclusions 
The binding and cellular uptake of RGD-coated and non-coated Nile Red-filled 
protein microspheres by a panel of cancer cells was studied in this chapter. The expression of 
the αvβ3 integrin receptor for this panel of cancer cell lines was characterized and quantified 
using flow cytometry and indirect immunofluorescence staining of surface antigens. The 
RGD-coated and non-coated protein microspheres were incubated with cancer cell lines of 
varying expressions of the αvβ3 integrin receptor to study the binding specificity and affinity 
of the microsphere to the integrin receptor. Based on the flow cytometry results, two cell lines 
(MDA-MB-231, MDA-MB-435S) had the highest expression of the αvβ3 integrin receptor by 
at least one order of magnitude. These particular cell lines had been reported as being highly 
metastatic with overexpression of the αvβ3 integrin receptor [24-26]. The binding specificity 
of Nile Red-filled microspheres to the cancer cells was quantified using fluorescence 
microscopy. Based on the fluorescence microscopy data and the flow cytometry data, the use 
of RGD to target the microspheres to the αvβ3 integrin receptor correlated closely with the 
integrin receptor expression on the cell surface. The cellular uptake and degradation of protein 
microspheres by the cancer cells was demonstrated by the diffuse fluorescent dye across the 
surface area of the cell under both fluorescence microscopy and confocal fluorescence 
microscopy. Due to the size of the microsphere, the nonspecific staining of the entire cell by 
the Nile Red, and the binding of the microsphere by the cell via the αvβ3 integrin receptor, the 
most likely method of cellular uptake of the microsphere is endocytosis. Currently published 
studies of LBL particles up to several micrometers in size were also internalized by epithelial 
cells, monocytes, and dendritic cells via endocytosis [8]. 
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CHAPTER 7 
FUTURE DIRECTIONS AND CONCLUSIONS 
7.1 Optical Coherence Tomography in Breast Cancer 
The initial studies presented in this thesis reveal that OCT is a very promising 
technology for the field of oncology, in particular breast cancer. I have shown that OCT 
provides real-time intraoperative feedback about the status of tumor margins and lymph 
nodes, and has the potential to be an invaluable aid for the diagnosis as well as surgical 
resection of malignant tissue. These initial studies could be further expanded as we develop 
OCT technology for translation into the clinic. This section will focus largely on the potential 
future directions of structural OCT in cancer detection, diagnosis, and treatment. 
The first direction is the development and assessment of automated methods for 
classifying the OCT data. Preliminary research in different types of tissues (tumor, adipose, 
stromal) suggests promising methods for automating the classification of OCT images, which 
include power attenuation of the OCT signal and the spatial frequency of scatterers along a 
single axial scan [1-4]. A potential limitation of these two methods is the assumption that the 
tissue is homogeneous along the depth of an axial scan. Further studies should determine the 
effects of tissue heterogeneity on the ability to classify different regions as tumor, stromal, or 
fat tissue. Recent advances in the acquisition speeds of OCT systems, the move to three-
dimensional imaging, and increases in resolution will enable the development of crucial 
algorithms that can initially and rapidly identify suspicious areas for the physician or trained 
OCT user. 
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The second direction is to extend the scope of the studies presented in this thesis into 
larger clinical studies. There are several other factors that would provide additional value to 
the development of OCT for the assessment of breast cancer. It would be important to 
determine how demographic information such as patient age or past surgical history affects 
the interpretation of OCT images. 
The average age of patients enrolled in the study reported in this thesis was 64. 
Younger patients are expected to have less fat tissue and more stromal tissue in the breast than 
older patients. Previous reports indicate that the bulk refractive index of stromal tissue is 
similar to the refractive index of tumor tissue; hence, an increasing challenge for the 
development of OCT technology will be the ability to differentiate abnormal tissue from 
healthy surrounding tissue, particularly in younger patients. With a larger pool of patients, the 
potential to image and assess smaller specimens and smaller lesions will increase. 
Prior surgical procedures on breast tissue that lead to the introduction of scarred tissue 
could affect OCT-based detection of cancerous tissue. A large scale clinical study of the 
intraoperative use of OCT in the assessment of breast cancer tumor margins and axillary 
lymph nodes would be necessary for investigating and addressing the following factors: 
system-to-system variability, user-to-user variability during acquisition, and user-to-user 
variability in data interpretation. With this study, the rates at which re-operation occurs to 
remove additional breast tissue to close or positive margins would be an important short-term 
outcomes assessment since additional surgeries exposes the patient to additional surgical risks 
such as infections and lymphadenopathy. Once OCT is validated in larger clinical trials, the 
impact of intraoperative OCT imaging can be evaluated through outcomes-based studies. One 
study could determine the effects of OCT intervention in the assessment of tumor margins and 
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the rate of local recurrence and metastatic spread of the cancer. A second study would 
determine the effects of OCT intervention in lymph node resection and the development of 
complications such as lymphedema. 
In addition to the intraoperative application of OCT for breast cancer surgeries, this 
technology could be valuable in the field of pathology by guiding the sectioning of tissue 
specimens submitted for histopathological analysis. In the current standard of care, tissue 
specimens are vastly undersampled, and they are guided inefficiently and subjectively, most 
often by visual inspection and manual palpation. Usually no more than a series of ten to 
twenty histology sections are taken from tissue specimens with average sizes of 5 x 5 x 5 cm, 
or 125 cm3. The high scanning speeds currently available with OCT could enable rapid 
imaging of tissue specimens and could identify suspicious regions for further 
histopathological analysis. 
7.2 Protein Microspheres 
The methodologies for synthesizing and customizing protein microspheres have been 
studied in depth for the last two decades. Protein microspheres are demonstrated as a versatile 
and durable vehicle for encapsulating particles into the inner core, embedding particles into 
the protein shell, and layering thin films onto the microsphere surface using the layer-by-layer 
assembly method. 
The development of protein microspheres as a multi-modal contrast agent largely 
depends on the clinical application and stage of research (i.e. basic science, in vitro, animal, 
or human studies). For example, this thesis focused primarily on the development of a protein 
microsphere that could provide magnetic and fluorescence contrast. The aim of the research 
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was to bridge a wide-field fluorescence imaging system, commonly used to study drug 
delivery in small animals, with microscopic imaging using magnetomotive OCT. 
Fluorescence microscopy or confocal microscopy can be used to confirm the localization of 
the protein microspheres in tissues during histological analysis. 
Once the stage of research moves from a small animal model to larger animals and 
eventually to humans, the use of a fluorescence imaging system for in vivo monitoring of the 
circulation and localization of microspheres will no longer be useful. At these scale ranges, 
the penetration depth for fluorescence imaging will be severely diminished. This issue was 
already observed when using rats instead of mice to study in vivo targeting of the RGD-coated 
protein microspheres discussed in Chapter 6. In such cases, other wide field imaging 
modalities with deeper penetration depths such as MRI or ultrasound imaging should be 
explored. 
The modifications made to target protein microspheres primarily focused on the use of 
a linear RGD peptide. The flow cytometry and fluorescence imaging data demonstrated that 
linear RGD-coated microspheres effectively bound to cancer cells expressing high levels of 
the αvβ3 integrin receptor. Fluorescence imaging data still revealed levels of non-specific 
binding of the RGD-coated protein microspheres to the cells. In order to improve the targeting 
capabilities of the protein microspheres, additional research will need to be performed to 
increase the level of specific binding of the protein microspheres to the αvβ3 integrin receptor. 
Several other modifications could be explored for increasing the binding specificity to αvβ3 
integrin receptors. The first would be a quantitative determination of the coverage of 
RGDKKKKKK layered on the surface of protein microspheres. SEM results suggested that 
the RGD sequence was not uniformly layered and did not fully cover the surface of the 
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microspheres. However, it is not clear whether any of the procedures used to process the 
microspheres for SEM and TEM analysis had any impact on the RGD peptide layer. Once the 
amount of RGD coating on microspheres is quantified, methods for increasing the coverage of 
the linear RGD peptide can be investigated. Questions that may be important to test include: 
whether the length of the poly-lysine residues contained in the RGD sequence alters binding 
to the protein microspheres, and whether there is difference in the layering of linear RGD vs. 
cyclic RGD onto the microspheres. Many studies suggest that cyclic RGD has a higher 
binding specificity and affinity to the αvβ3 integrin receptor than linear RGD [5-8]. The 
circulation lifetime of cyclic RGD was found to be higher than that of linear RGD; cyclic 
RGD was not as quickly degraded and cleared from the body as linear RGD [5-8]. 
The RGD peptide sequence is known to bind to a family of integrin receptors, which 
supports non-specific binding of RGD-coated protein microspheres to other receptors aside 
from αvβ3 integrins. The use of monoclonal antibodies targeted against both the alpha and beta 
subunits of the integrin receptor could help increase binding specificity and decrease non-
specific binding of the protein microspheres to cells. Based on published reports, it is possible 
to use click chemistry for doing covalent LBL assembly instead of depending solely on 
electrostatic or hydrogen bonding interactions employed by traditional LBL assembly [9]. 
This method was used to couple monoclonal antibodies functionalized with an azide group to 
a capsule surface containing alkynes [9, 10]. 
In addition to the contrast and targeting properties of the protein microspheres 
described in this thesis, further applications of protein microspheres were mentioned in 
Chapter 4, ranging from the encapsulation of hydrophobic drugs to the encapsulation of heat 
absorbing particles to induce hyperthermia. Before any major studies are undertaken to 
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explore the use of protein microspheres as therapeutic agents, further in vitro and in vivo work 
should be performed to study the mechanisms and consequences of the cellular uptake of the 
protein microspheres. αvβ3 integrins can mediate endocytosis of the ligands bound to this 
receptor [11-13], suggesting a role of integrins in the cellular uptake of microspheres 
observed in studies described in this thesis. Cellular uptake and degradation of microspheres 
enabling the release of encapsulated therapeutic agents would be desired in applications 
where diseased cells are targeted; however, for imaging purposes in which the microspheres 
serve as contrast agents, destruction of the microspheres would render this application useless. 
Studying the mechanisms of cellular uptake will provide insights in the design of the protein 
microsphere as targeted therapeutic agents.  
7.3 In Vitro Targeting of Protein Microspheres 
RGD-coated protein microspheres were used for in vitro studies targeting αvβ3 integrin 
receptors expressed on the cell surface of a variety of cancer cell lines. The previous 
discussion focused on increasing the binding specificity of the protein microspheres to the 
αvβ3 integrin receptor by identifying methods for increasing the RGD coating of 
microspheres. The in vitro studies reported in this thesis used single cell monolayers to 
quantify and compare microsphere binding to integrin receptors exposed on the cell surface. 
In this configuration, the basal sides of the cells were not exposed to protein microspheres. 
Since integrins mediate cell-substrate adhesion, it is conceivable that a significant portion of 
the integrin receptors may be located at the junction between the cell and the Petri dish rather 
than being exposed at the apical side of the cells. Other methods should be explored for 
studying the dynamics of binding between free floating protein microspheres and cancer cells 
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to better mimic the physiological environment in which protein microspheres would bind to 
circulating tumor cells located in the vasculature or lymphatic system. 
In order to extend initial findings that suggested that protein microspheres were 
readily engulfed by cancer cells via endocytosis and degraded by the cells, studies should be 
performed to identify the timescale of microsphere binding and destruction by cells. Based on 
the studies presented in Chapter 6, the encapsulated Nile Red from the microspheres was 
found localized to the cell. Performing confocal fluorescence microscopy would provide 
better information about whether the dye localizes to the cell membrane or to the cell 
cytoplasm. 
An increased understanding about the interactions between microspheres and cells 
would guide the development of microcapsules for cellular therapeutic delivery. This would 
be the first step towards the molecular targeting of therapeutics using protein microspheres. If 
cells readily uptake the protein microspheres, then the development of external methods to 
rupture the microspheres or induce hyperthermia using the microspheres may not be 
necessary. Further, toxicity studies of the protein microspheres and encapsulated particles 
should be carried out to determine the effects of non-specific binding of these protein 
microspheres. 
7.4 Ex Vivo and In Vivo Targeting of Protein Microspheres in Cancer Animal Models 
Previous studies using protein microspheres in animals were largely focused at the 
bio-distribution of non-targeted protein microspheres in vivo or on demonstrating increased 
non-specific contrast in organs [14-16]. In earlier studies, I looked at whether iron oxide-filled 
protein microspheres could be detected by MM-OCT under a number of different 
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microenvironments: microspheres in an agarose gel, microspheres inside of macrophages in 
an agarose gel, and microspheres injected into tumor tissue. The results, in Figure 7.1, 
indicated the ability to see individual or small aggregates of iron oxide-filled protein 
microspheres under both low-scattering and high-scattering microenvironments. 
 
 
 
 
Agarose Gel 
 
 
Macrophages in 
Agarose Gel 
 
Intra-Tumor Injection 
 
Figure 7.1: Iron oxide-filled protein microspheres embedded in agarose gel (top row). Iron 
oxide-filled protein microspheres uptaken by macrophages subsequently embedded in an 
agarose gel (middle row). Iron oxide-filled protein microspheres that were injected into a 
tumor sample from an NMU carcinogen induced rat.  
 
 
 
 
The studies presented in this thesis are the first attempts at using targeted protein 
microspheres in vitro for cancer applications. A wide-field fluorescence imaging system was 
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initially identified for its ease of use and its potential for in vivo tracking of fluorescent 
microspheres. In a preliminary animal model experiment with the NMU carcinogen induced 
rat animal model, RGD-coated Nile Red-filled protein microspheres were injected via the tail 
vein as a bolus injection. This initial experiment showed some very promising results where 
the RGD-coated protein microspheres traveled to and aggregated to the locations of the 
tumors and lymph nodes (Figure 7.2). At the end of this time period, the rat was euthanized 
and dissected. The tumors and surrounding tissue were imaged with the wide-field 
fluorescence imaging system which identified the protein microspheres not only at the tumor 
site but clearly delineating the extensive vascular and lymphatic system that surrounded the 
tumor (Figure 7.3). Upon further dissection, it was also observed that the protein 
microspheres had traveled to and localized to the abdominal lymph nodes (Figure 7.3). 
Studies are still ongoing to test the in vivo targeting of RGD-coated protein 
microspheres in an animal cancer model. As further studies were undertaken to further 
investigate the preliminary results above, several issues were identified that should be 
addressed in future in vivo targeting animal studies. As described in Chapters 4 and 5 of this 
thesis, the microspheres designed for this system were imaged in gel phantoms. Despite 
characterization and systematic optimization of the fluorescent protein microspheres for this 
system, the microspheres were not readily visible during in vivo administration in rats. The 
main reasons were attributed to the use of an inappropriate animal cancer model. The larger 
size of a rat interfered with the ability to monitor the in vivo circulation of the protein 
microspheres. Furthermore, although the rat hair was shaved off, the thick rat skin largely 
interfered with the ability to visualize fluorescent microspheres deeper in the rat tissue. Future 
studies of the in vivo targeting of protein microspheres could be done with nude mice.  
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Figure 7.2: Wide-field fluorescence imaging of a NMU carcinogen induced rat animal in real 
time. The RGD-coated Nile Red-filled protein microspheres were injected at time 0. The time 
scale shown above is at 0 hrs 0 mins on the first image to 1 hrs 42 mins on the last image.   
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Figure 7.3: Wide-field fluorescence imaging of the two tumor sites, the abdominal lymph 
nodes, and the skin from the site of the 2nd tumor in the NMU carcinogen induced rat animal. 
The skin sample showed that the microspheres were present in vast extensive network of 
blood vessels and lymph vessels surrounding the tumor. 
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A more appropriate mouse tumor model should be developed and characterized for 
testing the in vivo targeting of microspheres. The RGD-coated microspheres were designed to 
target the vasculature with high levels of expression of the αvβ3 integrin receptor since their 
large size precludes them from migrating from the lumen of the vasculature into the 
extracellular matrix to reach the cancer cells. During tumor angiogenesis, it is known that the 
tumor vasculature has elevated expression of the αvβ3 integrin receptors as the tumor tries to 
recruit the development of new blood vessels. Tumor angiogenesis occurs once the tumor is 
larger than a few millimeters and can no longer support itself from the passive diffusion of 
nutrients. 
Preliminary results for a NMU-carcinogen induced rat tumor model, a spontaneous 
tumor model indicated that the maximum expression of the integrin receptor occurred at 
tumor sizes between 0.5 cm and 1.0 cm. This rat tumor model has been shown to most closely 
mimic the natural development and progression of human breast tumors notably ductal 
carcinoma in situ. Although the NMU carcinogen induced mammary tumors in normal rats, 
the injection of the NMU carcinogen in nude rats and mice did not form any tumors. 
Another tumor model available in Prof. Boppart’s laboratory is a xenograft model in 
which MAT III 13762 cells (a rat mammary cancer cell line) are injected sub-cutaneously or 
intraperitoneally into the rat. This model successfully forms tumors within 2-3 weeks of 
injection. However, as characterized by in vitro work in Chapter 6, the MAT III 13762 cell 
line does not highly express the αvβ3 integrin receptor in vitro. Similar to the quantification of 
the αvβ3 integrin receptor in vitro, the receptor expression should be quantified for the tumors 
and vasculature in various animal models. A more suitable animal model may be the 
xenograft model using the two metastatic cell lines MDA-MB-231 or MDA-MB-435S, which 
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demonstrated high expression levels of αvβ3 integrins in vitro. However, it is unclear the 
expression of the αvβ3 integrin receptors on cancer cells is correlated to the integrin receptor 
expression in the neighboring vasculature. 
Studying the pharmacokinetics and pharmacodynamics of the protein microspheres in 
more detail will be instrumental for successfully monitoring the circulation and localization of 
targeted protein microspheres. In current animal experiments, protein microspheres were 
introduced into the tail vein using a syringe pump at a constant rate over 1 hr. However, since 
little is known about the rate of clearance of the microspheres from the circulation, it is 
difficult to determine an appropriate method and rate of injection. Available methods include 
the administration of microspheres in a single bolus injection, a bolus injection followed by a 
maintenance dose, or a continuous injection for an extended period of time. Because previous 
reports identified aggregation of protein microspheres at the site of injection or within the 
circulation, the continuous injection method was initially chosen over bolus injections to 
decrease the chances of aggregation. Although there appeared to be decreased fluorescence 
signals at the site of injection with continuous injections during, there were difficulties being 
able to reliably localize and quantify the fluorescence signal from the microspheres at the 
major organs. The results were also not reliably reproducible from one animal to another 
animal. Other methods of introducing the microspheres into the vasculature should be 
examined, including alternative injection sites. 
7.5 Ex Vivo and In Vivo Targeting of Protein Microspheres in Atherosclerosis  
As previously discussed in Chapter 1, the potential of the research presented in this 
thesis can also be applicable to the field of atherosclerosis. Since the targeting of the protein 
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microspheres is via the αvβ3 integrin receptor, any disease processes that involves 
inflammation, the activation of angiogenesis, and the proliferation of new blood vessels will 
also likely benefit from the results presented in this thesis. In atherosclerosis, the primary cell 
of interest is now the macrophage, which plays an integral role in the development and 
eventual rupture of atherosclerotic lesions and plaques. Macrophages embedded in an agarose 
gel and macrophages, previously incubated with iron oxide-filled protein microspheres, also 
embedded in an agarose gel were imaged under MM-OCT (Figure 7.4). Under the structural 
OCT image (red), the main scatterers observed correspond to individual macrophages. In the 
bottom row of images, the iron oxide-filled protein microspheres (green) can be seen under 
MM-OCT and can be seen localized inside the scattering macrophages (red). 
 
 
Figure 7.4: MM-OCT images of only macrophages (top row) embedded in an agarose gel. 
MM-OCT images of the macrophages previously incubated with iron oxide-filled protein 
microspheres embedded in an agarose gel. 
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Further preliminary studies were also performed in an atherosclerotic rat animal 
model. The rats were fed a high-cholesterol and high-fat diet for 10 weeks. The entire 
ascending aorta, aortic arch, and descending aorta were resected from the rat. The aorta was 
incubated at 37°C in cell media with iron oxide-filled protein microspheres for 4 hours. After 
the incubation period, the aorta was thoroughly flushed with saline. The aorta was then 
incubated at 37°C for an additional 2 hours in saline to remove any loose or excess protein 
microspheres. The aorta was then cut open and placed between a microscope slide and 
coverslip for imaging. The inner lumen of the aorta was placed facing down towards the 
microscope slide. A series of 17 MM-OCT images were taken approximately 1 mm apart 
from each other along the length of the aorta. H&E histological staining on the sample was 
also performed. MM-OCT results and corresponding histology from a rat that was fed a 
normal diet is shown in Figure 7.5. The average MM-OCT signal was found to be 0.0273 dB 
when averaged across the 17 images taken for this sample. The MM-OCT results and 
corresponding histology for the aorta from a rat that was on the high-fat and high-cholesterol 
diet are presented in Figure 7.6. The results show a localized area with a very strong MM-
OCT signal. This area correlates to an atherosclerotic lesion on the surface of the inner lumen 
of the aorta. When averaging the MM-OCT signal across all 17 images, the average signal 
was 0.329 dB. When averaging across the images with a significant MM-OCT signal (> 0.1 
dB), the average MM-OCT signal was found to be 0.931 dB across 5 images corresponding to 
the area of the atherosclerotic lesion. The average MM-OCT signal across the remaining 12 
images representing the normal areas of the aorta was found to be 0.0774 dB. This initial data 
was promising in demonstrating that the iron oxide-filled protein microspheres can be uptaken 
into the atherosclerotic lesions and can also be detected under MM-OCT. 
  227 
 
 
 
 
Figure 7.5: MM-OCT images of the aorta from a rat that was a fed a normal diet with 
corresponding histology with standard H&E staining. 
 
 
 
 
Figure 7.6: MM-OCT images of the aorta from a rat that was fed a high-fat and high-
cholesterol diet with corresponding histology with standard H&E staining. 
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7.6 Conclusions 
The overall goal of this thesis was to initially determine the utility of OCT for the 
intraoperative detection and assessment of cancer, particularly breast cancer. OCT was 
successfully demonstrated as a method for the intraoperative assessment of resected tumor 
margins [17, 18] and the visualization of axillary lymph nodes [19, 20]. An equally important 
goal of this thesis was to extend the utility of OCT for broader applications by coupling it 
with the development of a novel, targeted multi-modal contrast agent. With the RGD-coated 
magnetic and fluorescent microspheres, MM-OCT can be coupled with MRI and fluorescence 
imaging. By targeting the αvβ3 integrin receptor, MM-OCT can be used to image earlier stages 
of the tumor growth and development. I have developed the first multi-modal protein 
microsphere targeted for cancer cells and angiogenesis that can be imaged using MRI,     
MM-OCT, and fluorescence imaging.  
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